https://www.spreaker.com/podcast/medical-history-files--7196444
From ancient cures and medieval plagues to the birth of modern surgery and the fight against epidemics, we explore the unsung heroes, controversial figures, and pivotal moments in medical history. Each episode delves into meticulously researched accounts, offering a fresh perspective on the challenges and triumphs that define the healing arts.

New investigations into these fascinating medical narratives are published daily, Monday through Sunday, at 9:00 AM. Expect compelling storytelling that transforms complex historical facts into engaging and accessible insights, perfect for your daily dose of historical knowledge.

This podcast is for anyone curious about the origins of medical practices, the evolution of health sciences, or simply loves a well-told story from the past. If you've ever wondered about the "why" and "how" behind today's healthcare, Medical History Files is your indispensable guide.

Subscribe now and start your journey through the captivating world of medical history.]]>enTrue Crime© 2026 OBOMEDIA Creatorshttps://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/b43583e2dc3d20413acc2b90e4a5e0a5.jpghttps://www.spreaker.com/podcast/medical-history-files--7196444Sat, 08 Aug 2026 13:02:30 +0000Creator at ObomediaCreator at Obomediacreators@obomedia.comUncover the forgotten stories, groundbreaking discoveries, and bizarre practices that shaped modern medicine. Medical History Files brings to life the extraordinary tales from the annals of healthcare, revealing how our understanding of the human body...
From ancient cures and medieval plagues to the birth of modern surgery and the fight against epidemics, we explore the unsung heroes, controversial figures, and pivotal moments in medical history. Each episode delves into meticulously researched accounts, offering a fresh perspective on the challenges and triumphs that define the healing arts.

New investigations into these fascinating medical narratives are published daily, Monday through Sunday, at 9:00 AM. Expect compelling storytelling that transforms complex historical facts into engaging and accessible insights, perfect for your daily dose of historical knowledge.

This podcast is for anyone curious about the origins of medical practices, the evolution of health sciences, or simply loves a well-told story from the past. If you've ever wondered about the "why" and "how" behind today's healthcare, Medical History Files is your indispensable guide.

Subscribe now and start your journey through the captivating world of medical history.]]>falseepisodichttps://www.spreaker.com/episode/the-ambassador-who-died-on-the-operating-table-44-days-in-madrid--73098309
A German ambassador dies on an operating table in Madrid six weeks after arriving in Spain in the spring of 1943 - the official cause: a failed appendix surgery, but his widow believed otherwise, and the question she raised would remain unsettled for more than sixty years. How did a man who delivered ultimatums linked to deportations to Auschwitz and described his embassy as "a hydra with many heads" end up dead in 44 days - accident, conspiracy, or something in between?

In this episode, we follow the forty-four days between Hans-Adolf von Moltke's arrival in Madrid on 6 February 1943 and his death on 22 March 1943, tracing his decades-long diplomatic career, his family background, and the actions he took in those final weeks that tied him to deportations and embassy crises. What do those forty-four days reveal about the man who served a murderous regime with competence and occasional hesitation?

Person: Hans-Adolf von Moltke
Date of birth: 29 November 1884
Arrival in Madrid: 6 February 1943
Date of death: 22 March 1943
Departure of coffin: 26 March 1943 (to Breslau)

- Moltke arrived in Madrid on 6 February 1943 and died on 22 March 1943, a span of forty-four days.
- The official cause of death recorded was a failed appendix surgery.
- On 26 March 1943 a sealed coffin left Madrid bound for Breslau, the family crypt.
- Moltke joined the Nazi Party on 1 October 1937.
- He negotiated the German-Polish Non-Aggression Pact in January 1934 while posted in Warsaw.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098309Sun, 09 Aug 2026 13:00:04 +0000Creator at ObomediaThe Ambassador Who Died on the Operating Table: 44 Days in Madrid A German ambassador dies on an operating table in Madrid six weeks after arriving in Spain in the spring of 1943 - the official cause: a failed appendix surgery, but his widow...
A German ambassador dies on an operating table in Madrid six weeks after arriving in Spain in the spring of 1943 - the official cause: a failed appendix surgery, but his widow believed otherwise, and the question she raised would remain unsettled for more than sixty years. How did a man who delivered ultimatums linked to deportations to Auschwitz and described his embassy as "a hydra with many heads" end up dead in 44 days - accident, conspiracy, or something in between?

In this episode, we follow the forty-four days between Hans-Adolf von Moltke's arrival in Madrid on 6 February 1943 and his death on 22 March 1943, tracing his decades-long diplomatic career, his family background, and the actions he took in those final weeks that tied him to deportations and embassy crises. What do those forty-four days reveal about the man who served a murderous regime with competence and occasional hesitation?

Person: Hans-Adolf von Moltke
Date of birth: 29 November 1884
Arrival in Madrid: 6 February 1943
Date of death: 22 March 1943
Departure of coffin: 26 March 1943 (to Breslau)

- Moltke arrived in Madrid on 6 February 1943 and died on 22 March 1943, a span of forty-four days.
- The official cause of death recorded was a failed appendix surgery.
- On 26 March 1943 a sealed coffin left Madrid bound for Breslau, the family crypt.
- Moltke joined the Nazi Party on 1 October 1937.
- He negotiated the German-Polish Non-Aggression Pact in January 1934 while posted in Warsaw.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1292falsefullhttps://www.spreaker.com/episode/how-carman-filled-an-nfl-stadium-with-free-faith-and-why-it-mattered--73098303
A single night in October 1994 saw 71,132 people enter Texas Stadium without paying a ticket - the documented world record for the largest single Christian concert in history. How did a high-school dropout from Trenton, with no corporate backing and a nonprofit model that kept shows free, build an audience that massive on those exact terms?

In this episode, we tell the story of Carman Licciardello’s rise from Atlantic City casino stages to stadium-sized Christian performances, tracing the career choices, conversions, and industry setbacks that shaped his approach to ministry and music. What choices and experiences turned a casino performer into the most attended solo Christian artist in recorded history?

Person: Carman Licciardello Licciardello
Date: October 22, 1994
Location: Texas Stadium
Event: Largest single Christian concert (71,132 attendees)
Age at final performance mentioned: 65

- 71,132 people attended Carman’s Texas Stadium concert on October 22, 1994, without paying a single dollar.
- Carman was born January 19, 1956, in Trenton, New Jersey, and learned drums at about age five.
- He dropped out of high school at seventeen and performed in Atlantic City casinos as a teenager.
- By 1985, his song “The Champion” became the number one CCM song in the country and earned RIAA gold certification.
- Charisma magazine named him Favorite Male Vocalist three consecutive years: 1987, 1988, and 1989.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098303Sat, 08 Aug 2026 13:00:04 +0000Creator at ObomediaHow Carman Filled an NFL Stadium with Free Faith-and Why It Mattered A single night in October 1994 saw 71,132 people enter Texas Stadium without paying a ticket - the documented world record for the largest single Christian concert in history. How...
A single night in October 1994 saw 71,132 people enter Texas Stadium without paying a ticket - the documented world record for the largest single Christian concert in history. How did a high-school dropout from Trenton, with no corporate backing and a nonprofit model that kept shows free, build an audience that massive on those exact terms?

In this episode, we tell the story of Carman Licciardello’s rise from Atlantic City casino stages to stadium-sized Christian performances, tracing the career choices, conversions, and industry setbacks that shaped his approach to ministry and music. What choices and experiences turned a casino performer into the most attended solo Christian artist in recorded history?

Person: Carman Licciardello Licciardello
Date: October 22, 1994
Location: Texas Stadium
Event: Largest single Christian concert (71,132 attendees)
Age at final performance mentioned: 65

- 71,132 people attended Carman’s Texas Stadium concert on October 22, 1994, without paying a single dollar.
- Carman was born January 19, 1956, in Trenton, New Jersey, and learned drums at about age five.
- He dropped out of high school at seventeen and performed in Atlantic City casinos as a teenager.
- By 1985, his song “The Champion” became the number one CCM song in the country and earned RIAA gold certification.
- Charisma magazine named him Favorite Male Vocalist three consecutive years: 1987, 1988, and 1989.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1017falsefullhttps://www.spreaker.com/episode/how-a-1960s-safety-panic-killed-a-car-then-history-vindicated-it--73098301
The Corvair went from selling 26,000 cars in its first two days to a 93% collapse in sales within three years, and a 143‑page government study later found it handled at least as well as contemporaries. What sequence of decisions - an engineering fix rejected on cost grounds, a tire‑pressure workaround, lawsuits and a bestselling book - turned a commercial success into a cautionary legend?

In this episode, we tell the story of the Chevrolet Corvair, the engineering choices behind its rear‑engine swing axle, the rejected front anti‑roll bar, and how those choices, plus public controversy, reshaped consumer protection-ending with a government report that arrived seven years too late and raised the question: how did belief overtake engineering facts?

Person: Ed Cole
Date: October 2, 1959
Location: Willow Run plant, Ypsilanti, Michigan
Event: Initial two‑day sales of 26,000 cars
Status: Government study published three years after final production concluded

- 26,000 Corvairs sold in the first two days on the market (October 1959).
- The Corvair accounted for 35% of GM's total two‑day sales that opening weekend.
- Monza trim sold 11,926 units before the model year ended (by April 1960).
- Corvair sales collapsed by 93% over a three‑year period after initial success.
- A 143‑page government study concluded the Corvair handled at least as well as its contemporaries, published seven years after the last car rolled out.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098301Fri, 07 Aug 2026 13:00:04 +0000Creator at ObomediaHow a 1960s Safety Panic Killed a Car - Then History Vindicated It The Corvair went from selling 26,000 cars in its first two days to a 93% collapse in sales within three years, and a 143‑page government study later found it handled at least as...
The Corvair went from selling 26,000 cars in its first two days to a 93% collapse in sales within three years, and a 143‑page government study later found it handled at least as well as contemporaries. What sequence of decisions - an engineering fix rejected on cost grounds, a tire‑pressure workaround, lawsuits and a bestselling book - turned a commercial success into a cautionary legend?

In this episode, we tell the story of the Chevrolet Corvair, the engineering choices behind its rear‑engine swing axle, the rejected front anti‑roll bar, and how those choices, plus public controversy, reshaped consumer protection-ending with a government report that arrived seven years too late and raised the question: how did belief overtake engineering facts?

Person: Ed Cole
Date: October 2, 1959
Location: Willow Run plant, Ypsilanti, Michigan
Event: Initial two‑day sales of 26,000 cars
Status: Government study published three years after final production concluded

- 26,000 Corvairs sold in the first two days on the market (October 1959).
- The Corvair accounted for 35% of GM's total two‑day sales that opening weekend.
- Monza trim sold 11,926 units before the model year ended (by April 1960).
- Corvair sales collapsed by 93% over a three‑year period after initial success.
- A 143‑page government study concluded the Corvair handled at least as well as its contemporaries, published seven years after the last car rolled out.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1105falsefullhttps://www.spreaker.com/episode/the-bakery-that-tried-to-kill-hong-kong-but-failed-spectacularly--73098298
Violence and survival collided over breakfast: between 300 and 500 people in Hong Kong were violently poisoned on January 15, 1857 after eating bread from a single bakery, yet zero people died because the arsenic dose was so massive it forced vomiting and expulsion. Who put enough arsenic in those loaves to “kill half the European population” and why did the man who baked them leave the city before anyone could arrest him?

In this episode, we lay out the sequence of events, the forensic tests that identified arsenic trioxide in the finished bread, and the legal aftermath that detained dozens of men while the bakery proprietor fled - but still left no convictions. How did a dose calculated at 60-64 grains per pound fail to become a massacre, and what did that paradox mean for colonial Hong Kong?

Person: Cheong Ah-lum
Date: January 15, 1857
Toxin: Arsenic trioxide
Victims: 300-500 people fell ill
Detentions: 52 Chinese men detained; 10 committed for trial

- Surgeon General Aurelius Harland instructed victims to induce vomiting and consume raw eggs, a treatment that helped prevent deaths.
- Three chemists confirmed arsenic in the finished loaves: Justus von Liebig calculated 64 grains per pound; John Ivor Murray calculated 62.3 grains per pound.
- No arsenic was found in flour, yeast, pastry, or table scrapings; contamination was present only in the baked bread.
- Cheong Ah-lum, proprietor of Esing Bakery, had already left Hong Kong before arrests began.
- The arsenic-laden bread was kept in the Chief Justice’s office for the next seventy-odd years without producing a final answer.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098298Thu, 06 Aug 2026 13:00:03 +0000Creator at ObomediaThe Bakery That Tried to Kill Hong Kong - But Failed Spectacularly Violence and survival collided over breakfast: between 300 and 500 people in Hong Kong were violently poisoned on January 15, 1857 after eating bread from a single bakery, yet zero...
Violence and survival collided over breakfast: between 300 and 500 people in Hong Kong were violently poisoned on January 15, 1857 after eating bread from a single bakery, yet zero people died because the arsenic dose was so massive it forced vomiting and expulsion. Who put enough arsenic in those loaves to “kill half the European population” and why did the man who baked them leave the city before anyone could arrest him?

In this episode, we lay out the sequence of events, the forensic tests that identified arsenic trioxide in the finished bread, and the legal aftermath that detained dozens of men while the bakery proprietor fled - but still left no convictions. How did a dose calculated at 60-64 grains per pound fail to become a massacre, and what did that paradox mean for colonial Hong Kong?

Person: Cheong Ah-lum
Date: January 15, 1857
Toxin: Arsenic trioxide
Victims: 300-500 people fell ill
Detentions: 52 Chinese men detained; 10 committed for trial

- Surgeon General Aurelius Harland instructed victims to induce vomiting and consume raw eggs, a treatment that helped prevent deaths.
- Three chemists confirmed arsenic in the finished loaves: Justus von Liebig calculated 64 grains per pound; John Ivor Murray calculated 62.3 grains per pound.
- No arsenic was found in flour, yeast, pastry, or table scrapings; contamination was present only in the baked bread.
- Cheong Ah-lum, proprietor of Esing Bakery, had already left Hong Kong before arrests began.
- The arsenic-laden bread was kept in the Chief Justice’s office for the next seventy-odd years without producing a final answer.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1264falsefullhttps://www.spreaker.com/episode/the-croquette-that-exposed-japan-s-biggest-food-fraud--73098293
A single DNA test in spring 2007 found pork, chicken, and unexplained meats inside a frozen beef croquette labeled “one hundred percent ground beef,” revealing an operation that shipped 9,838 tons of adulterated meat across 22 prefectures. How did a company lauded by the Ministry one month later secretly supply school lunches, military bases, and hospitals with contaminated and relabeled product for nearly three decades?

In this episode, we tell the documented story of Meat Hope Incorporated: what the company produced, the internal orders and government commendations that coexisted, and the whistleblower who filed anonymous complaints for six years. How did the system of concealment work, and why did reporting fail until that DNA test?

Person: Minoru Tanaka
Person: Kiroku Akahane
Date: Spring 2007
Event: DNA test on frozen beef croquette
Quantity: 9,838 tons of adulterated meat

- The package label claimed “one hundred percent ground beef” while the croquette contained pork, chicken, and other unexplained meats.
- The adulterated meat had reached recipients across 22 Japanese prefectures, including school lunch programs, military bases, and hospitals.
- In April 2006 Tanaka received a formal commendation from Japan’s Minister of Education, Culture, Sports, Science and Technology for a ground beef technique.
- In the same month managers issued an internal order to halt char siu pork production because additive levels exceeded permissible limits.
- Whistleblower Kiroku Akahane filed anonymous complaints repeatedly from 2000 through 2006 after observing relabeling, color correction with blood, reuse of returned product, and use of expired and decomposed meat.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098293Wed, 05 Aug 2026 13:00:02 +0000Creator at ObomediaThe Croquette That Exposed Japan's Biggest Food Fraud A single DNA test in spring 2007 found pork, chicken, and unexplained meats inside a frozen beef croquette labeled “one hundred percent ground beef,” revealing an operation that shipped 9,838...
A single DNA test in spring 2007 found pork, chicken, and unexplained meats inside a frozen beef croquette labeled “one hundred percent ground beef,” revealing an operation that shipped 9,838 tons of adulterated meat across 22 prefectures. How did a company lauded by the Ministry one month later secretly supply school lunches, military bases, and hospitals with contaminated and relabeled product for nearly three decades?

In this episode, we tell the documented story of Meat Hope Incorporated: what the company produced, the internal orders and government commendations that coexisted, and the whistleblower who filed anonymous complaints for six years. How did the system of concealment work, and why did reporting fail until that DNA test?

Person: Minoru Tanaka
Person: Kiroku Akahane
Date: Spring 2007
Event: DNA test on frozen beef croquette
Quantity: 9,838 tons of adulterated meat

- The package label claimed “one hundred percent ground beef” while the croquette contained pork, chicken, and other unexplained meats.
- The adulterated meat had reached recipients across 22 Japanese prefectures, including school lunch programs, military bases, and hospitals.
- In April 2006 Tanaka received a formal commendation from Japan’s Minister of Education, Culture, Sports, Science and Technology for a ground beef technique.
- In the same month managers issued an internal order to halt char siu pork production because additive levels exceeded permissible limits.
- Whistleblower Kiroku Akahane filed anonymous complaints repeatedly from 2000 through 2006 after observing relabeling, color correction with blood, reuse of returned product, and use of expired and decomposed meat.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1152falsefullhttps://www.spreaker.com/episode/one-tunnel-found-nearly-three-thousand-eight-hundred-people-made-homeless-the-zoo-was-gone--73098291
One tunnel, twenty-five feet deep and packed with explosives, triggered an operation that left nearly 3,800 people homeless and wiped out a zoo in Rafah - how did a single discovery justify demolishing seventy hectares of farmland and hundreds of homes? What sequence of orders, reversals, and actions turned a targeted mission into mass displacement?

In this episode, we lay out the documented record of Operation Rainbow in Rafah in May 2004, tracing the timeline, casualties, and demolitions that followed the tunnel discovery to ask whether the operation was a continuation of earlier policies or a distinct escalation.

Person: Sheikh Ahmed Yassin
Date: May 2004
Location: Rafah, Gaza Strip
Event: Operation Rainbow
Period: May 12-June 1, 2004

- One tunnel found: 25 feet deep, packed with explosives, at the southern edge of the Gaza Strip.
- Nearly 3,800 people made homeless and 70 hectares of farmland scraped from the earth after the operation.
- Fifty-nine Palestinians killed between May 12 and May 24, including 11 under the age of 18.
- Nearly 300 buildings destroyed during and around Operation Rainbow.
- Between April 1, 2003 and April 30, 2004, 487 houses in Rafah were demolished prior to the operation.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098291Tue, 04 Aug 2026 13:00:02 +0000Creator at ObomediaOne tunnel found. Nearly three thousand eight hundred people made homeless. The zoo was gone One tunnel, twenty-five feet deep and packed with explosives, triggered an operation that left nearly 3,800 people homeless and wiped out a zoo in Rafah -...
One tunnel, twenty-five feet deep and packed with explosives, triggered an operation that left nearly 3,800 people homeless and wiped out a zoo in Rafah - how did a single discovery justify demolishing seventy hectares of farmland and hundreds of homes? What sequence of orders, reversals, and actions turned a targeted mission into mass displacement?

In this episode, we lay out the documented record of Operation Rainbow in Rafah in May 2004, tracing the timeline, casualties, and demolitions that followed the tunnel discovery to ask whether the operation was a continuation of earlier policies or a distinct escalation.

Person: Sheikh Ahmed Yassin
Date: May 2004
Location: Rafah, Gaza Strip
Event: Operation Rainbow
Period: May 12-June 1, 2004

- One tunnel found: 25 feet deep, packed with explosives, at the southern edge of the Gaza Strip.
- Nearly 3,800 people made homeless and 70 hectares of farmland scraped from the earth after the operation.
- Fifty-nine Palestinians killed between May 12 and May 24, including 11 under the age of 18.
- Nearly 300 buildings destroyed during and around Operation Rainbow.
- Between April 1, 2003 and April 30, 2004, 487 houses in Rafah were demolished prior to the operation.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1109falsefullhttps://www.spreaker.com/episode/how-antibiotics-taught-bacteria-to-kill-again-by-2050--73098289
Antibiotics turned once-common killers into manageable illnesses, yet by 2050 ten million people could die each year from infections medicine can no longer treat - caused not by new plagues but by ordinary bacteria taught to survive our drugs. How did a tool hailed as the twentieth century’s greatest medical achievement become the engine of a slow-moving catastrophe?

In this episode, we trace the history and mechanics of antibiotic resistance from Alexander Fleming’s 1928 discovery of penicillin through decades of clinical and agricultural practice, and ask how repeated use in hospitals and feedlots created strains that modern medicine struggles to control. What critical decisions and routine habits accelerated resistance until it became a global threat?

Person: Alexander Fleming
Date: 1928
Event: Discovery of penicillin
Topic: Antibiotic resistance spread via clinical overprescription and agricultural growth promotion
Program: National Antimicrobial Resistance Monitoring System (established 1996)

- By 2050, an estimated ten million people will die each year from untreatable infections.
- In roughly 75% of acute respiratory infection cases in outpatient clinics, patients leave with an antibiotic prescription.
- Between 90 and 90- (transcript cuts off) indicates extremely high antibiotic prescribing rates for bronchitis.
- More than 150 peer-reviewed articles have emerged from the National Antimicrobial Resistance Monitoring System documenting transmission links.
- The National Antimicrobial Resistance Monitoring System was established in 1996 involving the FDA, the CDC, and the USDA.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098289Mon, 03 Aug 2026 13:00:02 +0000Creator at ObomediaHow Antibiotics Taught Bacteria to Kill Again by 2050 Antibiotics turned once-common killers into manageable illnesses, yet by 2050 ten million people could die each year from infections medicine can no longer treat - caused not by new plagues but...
Antibiotics turned once-common killers into manageable illnesses, yet by 2050 ten million people could die each year from infections medicine can no longer treat - caused not by new plagues but by ordinary bacteria taught to survive our drugs. How did a tool hailed as the twentieth century’s greatest medical achievement become the engine of a slow-moving catastrophe?

In this episode, we trace the history and mechanics of antibiotic resistance from Alexander Fleming’s 1928 discovery of penicillin through decades of clinical and agricultural practice, and ask how repeated use in hospitals and feedlots created strains that modern medicine struggles to control. What critical decisions and routine habits accelerated resistance until it became a global threat?

Person: Alexander Fleming
Date: 1928
Event: Discovery of penicillin
Topic: Antibiotic resistance spread via clinical overprescription and agricultural growth promotion
Program: National Antimicrobial Resistance Monitoring System (established 1996)

- By 2050, an estimated ten million people will die each year from untreatable infections.
- In roughly 75% of acute respiratory infection cases in outpatient clinics, patients leave with an antibiotic prescription.
- Between 90 and 90- (transcript cuts off) indicates extremely high antibiotic prescribing rates for bronchitis.
- More than 150 peer-reviewed articles have emerged from the National Antimicrobial Resistance Monitoring System documenting transmission links.
- The National Antimicrobial Resistance Monitoring System was established in 1996 involving the FDA, the CDC, and the USDA.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1086falsefullhttps://www.spreaker.com/episode/the-note-that-stopped-a-cremation-nurse-morphine-forged-will--73098284
A single handwritten note halted a cremation and exposed a tangled web of false titles, a forged will, and a cache of morphine in an interwar nursing home; who really spoke for Ada Baguley, and why was a document sworn to her wishes convincing enough to almost let a body be cremated without question? The Medical Officer for Health's suspicion of that note led to a post-mortem that turned a routine death into one of the most disturbing medical-legal cases of 1935.

In this episode, we follow the sequence of events at 32 Devon Drive and the people who lived there, from Ada and her mother Louisa to Dorothea Nancy Waddingham and Ronald Joseph Joseph, tracing how a rewritten will, unused morphine, and a claimed nursing title reshaped the fate of an estate and raised urgent legal and medical questions: what did the post-mortem reveal, and who profited?

Person: Ada Baguley
Date: 12 September 1935
Location: 32 Devon Drive, Nottingham
Topic: forged will, unregistered nurse, morphine
Event: post-mortem ordered before cremation

- Ada Baguley was 32 years old and living with multiple sclerosis at the time of her death.
- Ada's estate was originally valued at £1,600 and held in trust for her mother Louisa with remainder to cousins.
- In May 1935 the will was rewritten to leave the entire estate to Dorothea Waddingham and Ronald Joseph.
- Louisa Baguley died in May 1935 at age 88 and was buried without a post-mortem.
- Morphine used by a previous patient, Mrs. Kemp, in February 1935 remained in the house and was unaccounted for.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098284Sun, 02 Aug 2026 13:00:02 +0000Creator at ObomediaThe Note That Stopped a Cremation: Nurse, Morphine, Forged Will A single handwritten note halted a cremation and exposed a tangled web of false titles, a forged will, and a cache of morphine in an interwar nursing home; who really spoke for Ada...
A single handwritten note halted a cremation and exposed a tangled web of false titles, a forged will, and a cache of morphine in an interwar nursing home; who really spoke for Ada Baguley, and why was a document sworn to her wishes convincing enough to almost let a body be cremated without question? The Medical Officer for Health's suspicion of that note led to a post-mortem that turned a routine death into one of the most disturbing medical-legal cases of 1935.

In this episode, we follow the sequence of events at 32 Devon Drive and the people who lived there, from Ada and her mother Louisa to Dorothea Nancy Waddingham and Ronald Joseph Joseph, tracing how a rewritten will, unused morphine, and a claimed nursing title reshaped the fate of an estate and raised urgent legal and medical questions: what did the post-mortem reveal, and who profited?

Person: Ada Baguley
Date: 12 September 1935
Location: 32 Devon Drive, Nottingham
Topic: forged will, unregistered nurse, morphine
Event: post-mortem ordered before cremation

- Ada Baguley was 32 years old and living with multiple sclerosis at the time of her death.
- Ada's estate was originally valued at £1,600 and held in trust for her mother Louisa with remainder to cousins.
- In May 1935 the will was rewritten to leave the entire estate to Dorothea Waddingham and Ronald Joseph.
- Louisa Baguley died in May 1935 at age 88 and was buried without a post-mortem.
- Morphine used by a previous patient, Mrs. Kemp, in February 1935 remained in the house and was unaccounted for.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1106falsefullhttps://www.spreaker.com/episode/when-trust-killed-canada-s-tainted-blood-and-the-5-000-verdict--73098282
Trust in a public system turned deadly: thirty thousand people were infected and eight thousand died or were expected to die, yet a court fine in May 2005 was only five thousand dollars - the statutory maximum. How did a trusted, decades-old blood system, run by the Canadian Red Cross and tied to Connaught Laboratories, allow preventable infections from HIV and hepatitis C to spread through hospitals and hemophilia treatments?

In this episode, we trace the timeline and decisions that shaped the tainted blood crisis, from the Red Cross’s dual role as operator and standard-setter to delayed testing and faulty processing, and ask whether warnings and alternatives were repeatedly ignored.

Person: Canadian Red Cross Society
Event: Tainted blood crisis
Date: May 2005 (five thousand dollar fine)
Period: 1940s-1990s
Case: Krever Commission inquiry

- Between 1985 and 1989 an estimated 1,250 Canadians were known to have contracted HIV through blood products.
- From March to November 1985 an estimated 133 Canadians were infected with HIV via transfusions before antibody screening began.
- The Red Cross delayed adopting the hepatitis C test from 1986 until 1990, a four-year gap.
- The Krever Commission estimated that 85% of hepatitis C infections between 1986 and 1990 were preventable.
- Seven children were infected after faulty heat-treatment was applied to Factor VIII plasma products in 1986-1987.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098282Sat, 01 Aug 2026 13:00:02 +0000Creator at ObomediaWhen Trust Killed: Canada's Tainted Blood-and the $5,000 Verdict Trust in a public system turned deadly: thirty thousand people were infected and eight thousand died or were expected to die, yet a court fine in May 2005 was only five thousand...
Trust in a public system turned deadly: thirty thousand people were infected and eight thousand died or were expected to die, yet a court fine in May 2005 was only five thousand dollars - the statutory maximum. How did a trusted, decades-old blood system, run by the Canadian Red Cross and tied to Connaught Laboratories, allow preventable infections from HIV and hepatitis C to spread through hospitals and hemophilia treatments?

In this episode, we trace the timeline and decisions that shaped the tainted blood crisis, from the Red Cross’s dual role as operator and standard-setter to delayed testing and faulty processing, and ask whether warnings and alternatives were repeatedly ignored.

Person: Canadian Red Cross Society
Event: Tainted blood crisis
Date: May 2005 (five thousand dollar fine)
Period: 1940s-1990s
Case: Krever Commission inquiry

- Between 1985 and 1989 an estimated 1,250 Canadians were known to have contracted HIV through blood products.
- From March to November 1985 an estimated 133 Canadians were infected with HIV via transfusions before antibody screening began.
- The Red Cross delayed adopting the hepatitis C test from 1986 until 1990, a four-year gap.
- The Krever Commission estimated that 85% of hepatitis C infections between 1986 and 1990 were preventable.
- Seven children were infected after faulty heat-treatment was applied to Factor VIII plasma products in 1986-1987.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1024falsefullhttps://www.spreaker.com/episode/before-dawn-the-pearl-roundabout-killings-that-left-no-justice--73098280
Before dawn, knives slit tent fabric and a fourteen-year-old named Jaffar slept beside his father - by 9:30 a.m. four peaceful protesters were dead and no one was ever convicted. How did a government security operation at Pearl Roundabout become, in witnesses' words, a massacre that left families with no justice?

In this episode, we lay out the timeline, the people, and the official findings that describe what happened between 3:00 a.m. and 9:30 a.m. on February 17, 2011, and ask how documented conclusions can coexist with unanswered questions about accountability.

Date: February 17, 2011
Location: Pearl Roundabout, Manama
Event: Dawn raid by security forces
Case: Four protesters killed; no convictions
Commission: Royal investigative commission created by the king

- Approximately 1,000 officers moved in from two directions at about 3:00 a.m., carrying sticks, shields, sound bombs, tear gas, and shotguns.
- More than 100 officers wore plainclothes; the National Security Agency and the Bahrain Defence Force were present.
- Four people who had gathered peacefully were killed between 3:00 a.m. and 9:30 a.m., and none of their killers were ever convicted.
- One victim, Ali Ahmed Moumen, 22, posted "My blood is sacrificed for my country" on Facebook hours before he was killed.
- The commission created by the king found that the four victims were unarmed.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098280Fri, 31 Jul 2026 13:00:02 +0000Creator at ObomediaBefore Dawn: The Pearl Roundabout Killings That Left No Justice Before dawn, knives slit tent fabric and a fourteen-year-old named Jaffar slept beside his father - by 9:30 a.m. four peaceful protesters were dead and no one was ever convicted. How...
Before dawn, knives slit tent fabric and a fourteen-year-old named Jaffar slept beside his father - by 9:30 a.m. four peaceful protesters were dead and no one was ever convicted. How did a government security operation at Pearl Roundabout become, in witnesses' words, a massacre that left families with no justice?

In this episode, we lay out the timeline, the people, and the official findings that describe what happened between 3:00 a.m. and 9:30 a.m. on February 17, 2011, and ask how documented conclusions can coexist with unanswered questions about accountability.

Date: February 17, 2011
Location: Pearl Roundabout, Manama
Event: Dawn raid by security forces
Case: Four protesters killed; no convictions
Commission: Royal investigative commission created by the king

- Approximately 1,000 officers moved in from two directions at about 3:00 a.m., carrying sticks, shields, sound bombs, tear gas, and shotguns.
- More than 100 officers wore plainclothes; the National Security Agency and the Bahrain Defence Force were present.
- Four people who had gathered peacefully were killed between 3:00 a.m. and 9:30 a.m., and none of their killers were ever convicted.
- One victim, Ali Ahmed Moumen, 22, posted "My blood is sacrificed for my country" on Facebook hours before he was killed.
- The commission created by the king found that the four victims were unarmed.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1197falsefullhttps://www.spreaker.com/episode/the-pin-that-proved-a-villain-how-thani-oruvan-was-born--73098278
A single displaced pin in a photograph of a former Miss World became the quietly terrifying image at the center of Thani Oruvan, a Tamil thriller released on August 28, 2015. The film was conceived in 2008, shot on celluloid across multiple Indian locations, and overcame a collapsed budget and a distributor who later walked away - so how did a tiny detail and massive obstacles create one of that year's most unsettling villains?

In this episode, we tell how a project greenlit by AGS Entertainment moved from a seven‑year concept to a finished film, following casting choices, production decisions, and financial crises, and we ask what the team sacrificed to keep their vision intact.

Person: Director Mohan Raja
Person: Lead actor Ravi Mohan
Person: Antagonist actor Arvind Swamy
Date: August 28, 2015 (film release)
Budget: Planned 15 crore rupees; final exceeded 20 crore rupees

- The concept for Thani Oruvan was first put into motion as early as 2008.
- Principal photography began on December 6, 2013, at Binny Mills in Chennai.
- Nayanthara was signed in Tamil 2013 to play opposite Ravi Mohan.
- Arvind Swamy was confirmed as the antagonist in Tamil 2014 after nearly two decades away from Tamil cinema.
- Director Mohan Raja and lead actor Ravi Mohan forfeited their salaries when the budget shortfall threatened production.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098278Thu, 30 Jul 2026 13:00:02 +0000Creator at ObomediaThe Pin That Proved a Villain: How Thani Oruvan Was Born A single displaced pin in a photograph of a former Miss World became the quietly terrifying image at the center of Thani Oruvan, a Tamil thriller released on August 28, 2015. The film was...
A single displaced pin in a photograph of a former Miss World became the quietly terrifying image at the center of Thani Oruvan, a Tamil thriller released on August 28, 2015. The film was conceived in 2008, shot on celluloid across multiple Indian locations, and overcame a collapsed budget and a distributor who later walked away - so how did a tiny detail and massive obstacles create one of that year's most unsettling villains?

In this episode, we tell how a project greenlit by AGS Entertainment moved from a seven‑year concept to a finished film, following casting choices, production decisions, and financial crises, and we ask what the team sacrificed to keep their vision intact.

Person: Director Mohan Raja
Person: Lead actor Ravi Mohan
Person: Antagonist actor Arvind Swamy
Date: August 28, 2015 (film release)
Budget: Planned 15 crore rupees; final exceeded 20 crore rupees

- The concept for Thani Oruvan was first put into motion as early as 2008.
- Principal photography began on December 6, 2013, at Binny Mills in Chennai.
- Nayanthara was signed in Tamil 2013 to play opposite Ravi Mohan.
- Arvind Swamy was confirmed as the antagonist in Tamil 2014 after nearly two decades away from Tamil cinema.
- Director Mohan Raja and lead actor Ravi Mohan forfeited their salaries when the budget shortfall threatened production.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1147falsefullhttps://www.spreaker.com/episode/they-gave-prisoners-lsd-for-77-days-who-consented--73098275
Astonishingly, for seventy-seven consecutive days in 1956 incarcerated men at the U.S. Public Health Service Hospital in Lexington, Kentucky, were dosed daily with LSD until by day three the drug stopped working and the researchers quadrupled the dose. Who were these men, how were they compensated, and what did "consent" mean inside a locked federal ward where access to opiates depended on cooperation?

In this episode, we lay out the facts documented in the record: the institutional setting, the lead researcher, the daily dosing schedule, and the missing disclosures that followed these experiments. How did published papers that shaped global drug policy omit the way subjects were paid, and what question about voluntary consent does that omission leave unanswered?

Person: Harris Isbell
Location: U.S. Public Health Service Hospital, Lexington, Kentucky
Period: 1956 (LSD dosing), Isbell director for 18 years starting 1945
Topic: Daily LSD dosing of incarcerated men and nondisclosure of compensation
Status: Research findings cited by World Health Organization and governments

- Seventy-seven consecutive days: daily LSD dosing occurred in 1956 inside a locked federal ward.
- By day three of dosing, the clinical record reports that LSD effects had nearly vanished due to rapid tolerance.
- Researchers responded to tolerance by quadrupling the LSD dose after the effect diminished.
- The Addiction Research Center published more than 125 papers while not disclosing that subjects were compensated with morphine and heroin.
- In 1962 Harris Isbell received the U.S. Public Health Service Meritorious Service Award and praise from Attorney General Robert F. Kennedy.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098275Wed, 29 Jul 2026 13:00:02 +0000Creator at ObomediaThey Gave Prisoners LSD for 77 Days - Who Consented? Astonishingly, for seventy-seven consecutive days in 1956 incarcerated men at the U.S. Public Health Service Hospital in Lexington, Kentucky, were dosed daily with LSD until by day three the drug...
Astonishingly, for seventy-seven consecutive days in 1956 incarcerated men at the U.S. Public Health Service Hospital in Lexington, Kentucky, were dosed daily with LSD until by day three the drug stopped working and the researchers quadrupled the dose. Who were these men, how were they compensated, and what did "consent" mean inside a locked federal ward where access to opiates depended on cooperation?

In this episode, we lay out the facts documented in the record: the institutional setting, the lead researcher, the daily dosing schedule, and the missing disclosures that followed these experiments. How did published papers that shaped global drug policy omit the way subjects were paid, and what question about voluntary consent does that omission leave unanswered?

Person: Harris Isbell
Location: U.S. Public Health Service Hospital, Lexington, Kentucky
Period: 1956 (LSD dosing), Isbell director for 18 years starting 1945
Topic: Daily LSD dosing of incarcerated men and nondisclosure of compensation
Status: Research findings cited by World Health Organization and governments

- Seventy-seven consecutive days: daily LSD dosing occurred in 1956 inside a locked federal ward.
- By day three of dosing, the clinical record reports that LSD effects had nearly vanished due to rapid tolerance.
- Researchers responded to tolerance by quadrupling the LSD dose after the effect diminished.
- The Addiction Research Center published more than 125 papers while not disclosing that subjects were compensated with morphine and heroin.
- In 1962 Harris Isbell received the U.S. Public Health Service Meritorious Service Award and praise from Attorney General Robert F. Kennedy.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1227falsefullhttps://www.spreaker.com/episode/when-routine-care-breaks-bones-the-case-that-made-medicine-law--73098271
A single hospital procedure left a voluntary patient with fractures of both acetabula after electroconvulsive therapy, and the court found no one at fault - a ruling that became the legal standard for medical negligence in England and Wales for six decades. What did the judge tell the jury that allowed routine omissions - no muscle relaxant, no restraints, and no warning - to be lawful, and who paid the price for that claim named only by a surname?

In this episode, we tell the story of the Bolam case, laying out the facts of the treatment, the missing safeguards, and the courtroom testimony that set a precedent. We track how professional norms about ECT, restraints, muscle relaxants and disclosure shaped the decision and ask whether following standard practice should ever be the last word in negligence.

Person: Mr Bolam
Event: Electroconvulsive therapy (ECT)
Injury: Fractures of both acetabula
Date: 1957
Location: Friern Hospital

- The patient was a voluntary inpatient who agreed to receive ECT.
- After the procedure he sustained fractures of the acetabula on both sides.
- Three measures were not used: no muscle relaxant drugs, no physical restraints, and no warning of fracture risk.
- By 1957, muscle relaxants were available but not universally used in ECT practice.
- The judge’s instruction to the jury produced a rule governing nearly every medical negligence claim in England and Wales for the next six decades.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098271Tue, 28 Jul 2026 13:00:02 +0000Creator at ObomediaWhen Routine Care Breaks Bones: The Case That Made Medicine Law A single hospital procedure left a voluntary patient with fractures of both acetabula after electroconvulsive therapy, and the court found no one at fault - a ruling that became the...
A single hospital procedure left a voluntary patient with fractures of both acetabula after electroconvulsive therapy, and the court found no one at fault - a ruling that became the legal standard for medical negligence in England and Wales for six decades. What did the judge tell the jury that allowed routine omissions - no muscle relaxant, no restraints, and no warning - to be lawful, and who paid the price for that claim named only by a surname?

In this episode, we tell the story of the Bolam case, laying out the facts of the treatment, the missing safeguards, and the courtroom testimony that set a precedent. We track how professional norms about ECT, restraints, muscle relaxants and disclosure shaped the decision and ask whether following standard practice should ever be the last word in negligence.

Person: Mr Bolam
Event: Electroconvulsive therapy (ECT)
Injury: Fractures of both acetabula
Date: 1957
Location: Friern Hospital

- The patient was a voluntary inpatient who agreed to receive ECT.
- After the procedure he sustained fractures of the acetabula on both sides.
- Three measures were not used: no muscle relaxant drugs, no physical restraints, and no warning of fracture risk.
- By 1957, muscle relaxants were available but not universally used in ECT practice.
- The judge’s instruction to the jury produced a rule governing nearly every medical negligence claim in England and Wales for the next six decades.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1078falsefullhttps://www.spreaker.com/episode/the-dollar-that-turned-orphans-into-patients-duplessis-quiet-theft--73098269
Fear and outrage: in 1940s Quebec a bureaucratic twist turned thousands of healthy children into certified psychiatric patients for an extra $1.50 a day-on paper, overnight. How did a law from 1909, a government order-in-council, and a higher federal psychiatric subsidy combine to reclassify entire orphanages and funnel millions to religious institutions, while the children remained trapped and unpaid?

In this episode, we tell the episode’s account of how policy, money, and authority reshaped lives in mid-century Quebec and outline the key events and actors that made reclassification possible. What exactly did the Loi sur les Asiles d'aliénés and the Duplessis government enable, and why were so many safeguards absent or complicit?

Person: Maurice Duplessis
Period: 1944-1959 (Duplessis’ final term)
Law: Loi sur les Asiles d'aliénés (enacted 1909)
Subsidy difference: $1.50 per child per day
Estimate received: ~70 million Canadian dollars (religious groups, per 1999 report)

- Federal subsidy for orphan care was $1.25 per child per day.
- Federal subsidy for psychiatric patients was $2.75 per patient per day.
- An order-in-council reclassified orphanages as psychiatric hospitals overnight.
- A 1960s commission found one third of 22,000 patients were certified for financial reasons.
- Lauzon and Poirier (1999) estimated religious groups received approximately $70,000,000 through the mechanism.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098269Mon, 27 Jul 2026 13:00:02 +0000Creator at ObomediaThe Dollar That Turned Orphans into Patients: Duplessis' Quiet Theft Fear and outrage: in 1940s Quebec a bureaucratic twist turned thousands of healthy children into certified psychiatric patients for an extra $1.50 a day-on paper, overnight. How...
Fear and outrage: in 1940s Quebec a bureaucratic twist turned thousands of healthy children into certified psychiatric patients for an extra $1.50 a day-on paper, overnight. How did a law from 1909, a government order-in-council, and a higher federal psychiatric subsidy combine to reclassify entire orphanages and funnel millions to religious institutions, while the children remained trapped and unpaid?

In this episode, we tell the episode’s account of how policy, money, and authority reshaped lives in mid-century Quebec and outline the key events and actors that made reclassification possible. What exactly did the Loi sur les Asiles d'aliénés and the Duplessis government enable, and why were so many safeguards absent or complicit?

Person: Maurice Duplessis
Period: 1944-1959 (Duplessis’ final term)
Law: Loi sur les Asiles d'aliénés (enacted 1909)
Subsidy difference: $1.50 per child per day
Estimate received: ~70 million Canadian dollars (religious groups, per 1999 report)

- Federal subsidy for orphan care was $1.25 per child per day.
- Federal subsidy for psychiatric patients was $2.75 per patient per day.
- An order-in-council reclassified orphanages as psychiatric hospitals overnight.
- A 1960s commission found one third of 22,000 patients were certified for financial reasons.
- Lauzon and Poirier (1999) estimated religious groups received approximately $70,000,000 through the mechanism.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1245falsefullhttps://www.spreaker.com/episode/000-silent-deaths-why-malpractice-cases-vanish-in-hospitals--73098263
Four hundred thousand preventable hospital deaths occur in the U.S. every year, while only seventeen thousand malpractice claims are filed - leaving roughly three hundred and eighty-three thousand deaths without legal action. How did a system emerge that filters out so many grieving families before they even reach a courtroom?

In this episode, we trace the gap between documented preventable deaths and filed claims, showing what families must prove to bring a malpractice case and why decades of reforms have failed to narrow that gap. What exactly are the five legal elements that keep most cases from ever being litigated?

Person: John T. James, PhD
Date: 1984 estimate and 2008 cost analysis
Event: First systemic estimate of preventable hospital deaths
Topic: Five legal elements required for malpractice claims
Country: United States

- Estimate in 1984: between 44,000 and 98,000 preventable hospital deaths per year
- Later analysis by John T. James, PhD: 400,000 preventable hospital deaths annually
- CDC estimate: 75,000 annual deaths from hospital-acquired infections
- Medicare data (2000-2002): 1.14 million patient-safety incidents among beneficiaries
- Filed malpractice claims per year: 17,000 compared with approximately 400,000 preventable deaths

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098263Sun, 26 Jul 2026 13:00:02 +0000Creator at Obomedia,000 Silent Deaths: Why Malpractice Cases Vanish in Hospitals Four hundred thousand preventable hospital deaths occur in the U.S. every year, while only seventeen thousand malpractice claims are filed - leaving roughly three hundred and...
Four hundred thousand preventable hospital deaths occur in the U.S. every year, while only seventeen thousand malpractice claims are filed - leaving roughly three hundred and eighty-three thousand deaths without legal action. How did a system emerge that filters out so many grieving families before they even reach a courtroom?

In this episode, we trace the gap between documented preventable deaths and filed claims, showing what families must prove to bring a malpractice case and why decades of reforms have failed to narrow that gap. What exactly are the five legal elements that keep most cases from ever being litigated?

Person: John T. James, PhD
Date: 1984 estimate and 2008 cost analysis
Event: First systemic estimate of preventable hospital deaths
Topic: Five legal elements required for malpractice claims
Country: United States

- Estimate in 1984: between 44,000 and 98,000 preventable hospital deaths per year
- Later analysis by John T. James, PhD: 400,000 preventable hospital deaths annually
- CDC estimate: 75,000 annual deaths from hospital-acquired infections
- Medicare data (2000-2002): 1.14 million patient-safety incidents among beneficiaries
- Filed malpractice claims per year: 17,000 compared with approximately 400,000 preventable deaths

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1153falsefullhttps://www.spreaker.com/episode/000-dead-17-000-lawsuits-why-justice-fails-hospital-victims--73098261
Nearly 400,000 Americans die in hospitals each year from preventable errors, while only about 17,000 malpractice lawsuits are filed annually-what stops grieving families from reaching a courtroom? How can a system meant to deliver accountability and compensation allow such a gap to persist?

In this episode, we lay out the evidence and narratives that trace the gap between patient harm and legal redress, from landmark studies in 1984 to Medicare and CDC data in the early 2000s, and ask what structural features of the medical liability system produce this outcome.

Person: John T. James, PhD
Date: 1984 study cited; Medicare data from 2000-2002; October 2008 cost analysis
Event: Estimated 400,000 preventable hospital deaths per year
Case: Approximately 17,000 malpractice lawsuits filed per year

- 400,000 is the estimated number of unnecessary deaths inside American hospitals per year, according to John T. James.
- 17,000 is the approximate number of medical malpractice lawsuits filed across the United States in the same year.
- 44,000-98,000 was the 1984 estimated annual deaths from preventable hospital errors reported in the medical literature.
- 1.14 million patient-safety incidents were recorded in Medicare data across 37 million hospitalizations between 2000 and 2002.
- 75,000 patients were estimated by the CDC to die annually from hospital-acquired infections.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098261Sat, 25 Jul 2026 13:00:02 +0000Creator at Obomedia,000 Dead, 17,000 Lawsuits: Why Justice Fails Hospital Victims Nearly 400,000 Americans die in hospitals each year from preventable errors, while only about 17,000 malpractice lawsuits are filed annually-what stops grieving families from reaching a...
Nearly 400,000 Americans die in hospitals each year from preventable errors, while only about 17,000 malpractice lawsuits are filed annually-what stops grieving families from reaching a courtroom? How can a system meant to deliver accountability and compensation allow such a gap to persist?

In this episode, we lay out the evidence and narratives that trace the gap between patient harm and legal redress, from landmark studies in 1984 to Medicare and CDC data in the early 2000s, and ask what structural features of the medical liability system produce this outcome.

Person: John T. James, PhD
Date: 1984 study cited; Medicare data from 2000-2002; October 2008 cost analysis
Event: Estimated 400,000 preventable hospital deaths per year
Case: Approximately 17,000 malpractice lawsuits filed per year

- 400,000 is the estimated number of unnecessary deaths inside American hospitals per year, according to John T. James.
- 17,000 is the approximate number of medical malpractice lawsuits filed across the United States in the same year.
- 44,000-98,000 was the 1984 estimated annual deaths from preventable hospital errors reported in the medical literature.
- 1.14 million patient-safety incidents were recorded in Medicare data across 37 million hospitalizations between 2000 and 2002.
- 75,000 patients were estimated by the CDC to die annually from hospital-acquired infections.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1282falsefullhttps://www.spreaker.com/episode/000-silent-deaths-how-hospitals-hide-preventable-patient-killings--73098259
More Americans die each year inside hospitals from preventable errors than from stroke or diabetes - a peer‑reviewed estimate puts the toll at 400,000 - yet only about 17,000 malpractice lawsuits are processed annually; how can a system that costs billions fail to account for most of these deaths?

In this episode, we lay out the data behind estimates of preventable hospital deaths, track how those numbers changed from 1984 to the 2000s, and explain the legal architecture that often leaves documented negligence without remedy; what explains the gap between the scale of harm and the number of cases pursued?

Person: John T. James
Topic: Preventable hospital deaths
Date: 1984-2004 (studies cited across these years)
Event: 17,000 malpractice lawsuits processed per year
Estimate: 400,000 annual deaths (peer‑reviewed aggregation)

- 400,000 annual deaths is John T. James’s peer‑reviewed estimate of preventable deaths inside American hospitals.
- 17,000 malpractice lawsuits are processed in the United States each year, according to the transcript.
- The CDC’s figure for hospital deaths from infections is 75,000, a smaller, more narrowly defined count.
- A 1984 study originally estimated between 44,000 and 98,000 annual hospital deaths from medical errors.
- One third of malpractice claims in a 2013 BMJ Open study involve failure to diagnose, with death being the most common outcome.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098259Fri, 24 Jul 2026 13:00:04 +0000Creator at Obomedia,000 Silent Deaths: How Hospitals Hide Preventable Patient Killings More Americans die each year inside hospitals from preventable errors than from stroke or diabetes - a peer‑reviewed estimate puts the toll at 400,000 - yet only about 17,000...
More Americans die each year inside hospitals from preventable errors than from stroke or diabetes - a peer‑reviewed estimate puts the toll at 400,000 - yet only about 17,000 malpractice lawsuits are processed annually; how can a system that costs billions fail to account for most of these deaths?

In this episode, we lay out the data behind estimates of preventable hospital deaths, track how those numbers changed from 1984 to the 2000s, and explain the legal architecture that often leaves documented negligence without remedy; what explains the gap between the scale of harm and the number of cases pursued?

Person: John T. James
Topic: Preventable hospital deaths
Date: 1984-2004 (studies cited across these years)
Event: 17,000 malpractice lawsuits processed per year
Estimate: 400,000 annual deaths (peer‑reviewed aggregation)

- 400,000 annual deaths is John T. James’s peer‑reviewed estimate of preventable deaths inside American hospitals.
- 17,000 malpractice lawsuits are processed in the United States each year, according to the transcript.
- The CDC’s figure for hospital deaths from infections is 75,000, a smaller, more narrowly defined count.
- A 1984 study originally estimated between 44,000 and 98,000 annual hospital deaths from medical errors.
- One third of malpractice claims in a 2013 BMJ Open study involve failure to diagnose, with death being the most common outcome.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1102falsefullhttps://www.spreaker.com/episode/000-preventable-hospital-deaths-why-only-17-000-sued--73098256
Four hundred thousand preventable hospital deaths occur every year in the United States, yet courts see only seventeen thousand medical malpractice claims in the same period - a gap that exposes how ordinary acts like a missed diagnosis become legally invisible. How can routine errors that researchers traced for decades translate into so few lawsuits?

In this episode, we lay out the scale of preventable harm documented by researchers from 1984 onward and explain the legal requirements that filter most cases out of court, asking why the architecture of tort law leaves so many deaths unaddressed.

Person: John T. James
Date: 1984
Topic: Preventable hospital deaths
Event: Journal of Patient Safety publication
Country: United States

- John T. James published an analysis in the Journal of Patient Safety estimating 400,000 preventable hospital deaths per year.
- A 1984 study estimated between 44,000 and 98,000 preventable deaths annually.
- The CDC found 75,000 deaths per year from hospital-acquired infections alone.
- Researchers using Medicare data identified 1.14 million adverse incidents across 37 million hospitalizations.
- Approximately 17,000 medical malpractice claims are recorded annually in American courts, not all resulting in compensation.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098256Thu, 23 Jul 2026 13:00:13 +0000Creator at Obomedia,000 Preventable Hospital Deaths - Why Only 17,000 Sued? Four hundred thousand preventable hospital deaths occur every year in the United States, yet courts see only seventeen thousand medical malpractice claims in the same period - a gap that...
Four hundred thousand preventable hospital deaths occur every year in the United States, yet courts see only seventeen thousand medical malpractice claims in the same period - a gap that exposes how ordinary acts like a missed diagnosis become legally invisible. How can routine errors that researchers traced for decades translate into so few lawsuits?

In this episode, we lay out the scale of preventable harm documented by researchers from 1984 onward and explain the legal requirements that filter most cases out of court, asking why the architecture of tort law leaves so many deaths unaddressed.

Person: John T. James
Date: 1984
Topic: Preventable hospital deaths
Event: Journal of Patient Safety publication
Country: United States

- John T. James published an analysis in the Journal of Patient Safety estimating 400,000 preventable hospital deaths per year.
- A 1984 study estimated between 44,000 and 98,000 preventable deaths annually.
- The CDC found 75,000 deaths per year from hospital-acquired infections alone.
- Researchers using Medicare data identified 1.14 million adverse incidents across 37 million hospitalizations.
- Approximately 17,000 medical malpractice claims are recorded annually in American courts, not all resulting in compensation.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1088falsefullhttps://www.spreaker.com/episode/000-dead-17-000-lawsuits-america-s-invisible-medical-justice-gap--73098254
Four hundred thousand people die in American hospitals every year from preventable causes, yet only seventeen thousand malpractice lawsuits are filed annually - a gap of 383,000 deaths with no legal reckoning. How can peer-reviewed science, CDC infection tallies, and documented patient-safety incidents coexist with a legal system that processes so few claims?

In this episode, we lay out the data and the system that produces that discrepancy, drawing on peer-reviewed research by John T. James, CDC figures, and large-sample Medicare analyses to ask why the law captures so little of the harm: is it procedural barriers, evidence rules, or something else?

Person: John T. James, PhD
Date: October 2008 (one-month hospital error cost study)
Period: 1984-2010s (history of patient-safety estimates)
Event: CDC documented 75,000 hospital-acquired infection deaths per year
Case: 2000-2002 study of 37 million Medicare hospitalizations identifying 1.14 million patient-safety incidents

- Peer-reviewed estimate: 400,000 preventable hospital deaths per year (John T. James)
- Lawsuits filed: approximately 17,000 malpractice claims per year nationwide
- One-month cost: $324,000,000 in additional hospital costs from medical errors (October 2008)
- CDC figure: 75,000 deaths per year from hospital-acquired infections alone
- Medicare study: 1.14 million patient-safety incidents found in 37 million hospitalizations (2000-2002)

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098254Wed, 22 Jul 2026 13:00:03 +0000Creator at Obomedia,000 Dead, 17,000 Lawsuits: America's Invisible Medical Justice Gap Four hundred thousand people die in American hospitals every year from preventable causes, yet only seventeen thousand malpractice lawsuits are filed annually - a gap of 383,000...
Four hundred thousand people die in American hospitals every year from preventable causes, yet only seventeen thousand malpractice lawsuits are filed annually - a gap of 383,000 deaths with no legal reckoning. How can peer-reviewed science, CDC infection tallies, and documented patient-safety incidents coexist with a legal system that processes so few claims?

In this episode, we lay out the data and the system that produces that discrepancy, drawing on peer-reviewed research by John T. James, CDC figures, and large-sample Medicare analyses to ask why the law captures so little of the harm: is it procedural barriers, evidence rules, or something else?

Person: John T. James, PhD
Date: October 2008 (one-month hospital error cost study)
Period: 1984-2010s (history of patient-safety estimates)
Event: CDC documented 75,000 hospital-acquired infection deaths per year
Case: 2000-2002 study of 37 million Medicare hospitalizations identifying 1.14 million patient-safety incidents

- Peer-reviewed estimate: 400,000 preventable hospital deaths per year (John T. James)
- Lawsuits filed: approximately 17,000 malpractice claims per year nationwide
- One-month cost: $324,000,000 in additional hospital costs from medical errors (October 2008)
- CDC figure: 75,000 deaths per year from hospital-acquired infections alone
- Medicare study: 1.14 million patient-safety incidents found in 37 million hospitalizations (2000-2002)

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1204falsefullhttps://www.spreaker.com/episode/midnight-collapse-how-simufilam-s-science-vanished-and-patients-waited--73098251
There is a slow-motion intellectual horror in this story: a drug tested by hundreds of Alzheimer's patients rested almost entirely on data from one lab, and by November 25, 2024 the Phase III trials had failed and simufilam was declared dead - but the original data was never produced. How did a molecule called simufilam and a protein called filamin A come to carry sixteen million dollars of public research investment, only to evaporate alongside a criminal case dropped at midnight?

In this episode, we trace the arc from laboratory claims to clinical trials and a midnight legal collapse. We lay out how a single research program shaped a company's entire strategy, how co-authorship linked academia to industry, and why investigators kept finding the same missing piece: no underlying data. What does it mean for patients and science when the foundation cannot be verified?

Person: Hoau-Yan Wang
Person: Lindsay Burns
Company: Cassava Sciences
Event: Phase III trials failed and simufilam discontinued
Date: November 25, 2024

- Simufilam (PTI-125) was named by the United States Adopted Names council in August 2020.
- More than hundreds of patients enrolled in open-label studies beginning March 2020.
- The foundational mechanism was described in two papers published in 2012 (Journal of Neuroscience) and 2017 (Neurobiology of Aging).
- The NIH granted Cassava Sciences funding in 2018 to pursue early clinical trials.
- Sixteen million dollars in public research funds were connected to the work centered on filamin A.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098251Wed, 22 Jul 2026 02:57:43 +0000Creator at ObomediaMidnight Collapse: How Simufilam's Science Vanished and Patients Waited There is a slow-motion intellectual horror in this story: a drug tested by hundreds of Alzheimer's patients rested almost entirely on data from one lab, and by November 25,...
There is a slow-motion intellectual horror in this story: a drug tested by hundreds of Alzheimer's patients rested almost entirely on data from one lab, and by November 25, 2024 the Phase III trials had failed and simufilam was declared dead - but the original data was never produced. How did a molecule called simufilam and a protein called filamin A come to carry sixteen million dollars of public research investment, only to evaporate alongside a criminal case dropped at midnight?

In this episode, we trace the arc from laboratory claims to clinical trials and a midnight legal collapse. We lay out how a single research program shaped a company's entire strategy, how co-authorship linked academia to industry, and why investigators kept finding the same missing piece: no underlying data. What does it mean for patients and science when the foundation cannot be verified?

Person: Hoau-Yan Wang
Person: Lindsay Burns
Company: Cassava Sciences
Event: Phase III trials failed and simufilam discontinued
Date: November 25, 2024

- Simufilam (PTI-125) was named by the United States Adopted Names council in August 2020.
- More than hundreds of patients enrolled in open-label studies beginning March 2020.
- The foundational mechanism was described in two papers published in 2012 (Journal of Neuroscience) and 2017 (Neurobiology of Aging).
- The NIH granted Cassava Sciences funding in 2018 to pursue early clinical trials.
- Sixteen million dollars in public research funds were connected to the work centered on filamin A.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1187falsefullhttps://www.spreaker.com/episode/where-did-the-simufilam-data-vanish-the-filamin-a-mystery--73098249
Hope for months of life was funded with sixteen million dollars in federal grants-yet investigators later found zero original data to support the mechanism behind simufilam. How did a drug program that enrolled hundreds, sparked four simultaneous investigations, and ended with the announcement “the drug did not work” come to rest on no surviving primary records?

In this episode, we tell the story of the filamin A hypothesis and the simufilam program, tracing how a single laboratory’s data became the foundation for clinical trials and multimillion-dollar NIH funding. What exactly vanished from the record, and what does that mean for the patients and science that relied on it?

Person: Hoau-Yan Wang
Person: Lindsay Burns
Institution: City University of New York (CUNY)
Company: Pain Therapeutics / Cassava Sciences
Amount: $16,000,000

- The NIH funding related to this program totaled sixteen million dollars.
- The filamin A mechanism was primarily reported by one lab led by Hoau-Yan Wang.
- Foundational papers on filamin A’s role were published in 2008 and 2009 in PLOS One.
- By March 2020 Cassava Sciences launched open-label studies of simufilam with enrolled patients.
- The program ended on November 25, 2024 with the announcement that the drug did not work.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098249Wed, 22 Jul 2026 02:57:31 +0000Creator at ObomediaWhere Did the Simufilam Data Vanish? The Filamin A Mystery Hope for months of life was funded with sixteen million dollars in federal grants-yet investigators later found zero original data to support the mechanism behind simufilam. How did a drug...
Hope for months of life was funded with sixteen million dollars in federal grants-yet investigators later found zero original data to support the mechanism behind simufilam. How did a drug program that enrolled hundreds, sparked four simultaneous investigations, and ended with the announcement “the drug did not work” come to rest on no surviving primary records?

In this episode, we tell the story of the filamin A hypothesis and the simufilam program, tracing how a single laboratory’s data became the foundation for clinical trials and multimillion-dollar NIH funding. What exactly vanished from the record, and what does that mean for the patients and science that relied on it?

Person: Hoau-Yan Wang
Person: Lindsay Burns
Institution: City University of New York (CUNY)
Company: Pain Therapeutics / Cassava Sciences
Amount: $16,000,000

- The NIH funding related to this program totaled sixteen million dollars.
- The filamin A mechanism was primarily reported by one lab led by Hoau-Yan Wang.
- Foundational papers on filamin A’s role were published in 2008 and 2009 in PLOS One.
- By March 2020 Cassava Sciences launched open-label studies of simufilam with enrolled patients.
- The program ended on November 25, 2024 with the announcement that the drug did not work.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1149falsefullhttps://www.spreaker.com/episode/0-5-mg-sic-vs-400-mg-aspirin-compound-unnamed-human-stakes-potential-psychedelic-antidepressant-but-unconfirmed--73098247
A single line in a paper flagged with a Latin mark calls out an impossible dose: half a milligram - one-eightieth the weight of an aspirin - and that unexplained number has haunted six decades of research into a drug that made rodents act like they'd taken LSD. How did a molecule that produced clear psychedelic-like effects in animals, yet caused uncontrollable vomiting and produced no psychedelic reports in humans at 25 mg, remain a pharmacological ghost in the literature?

In this episode, we trace the molecule’s arc from its first synthesis in 1966 through animal studies, receptor mapping, and the sparse human data, and we ask what stalled its path to clinical clarity - is the answer buried in an embargoed doctoral thesis or in the messy biology of serotonin receptors?

Person: quipazine
Date: first reported 1966
Event: registered head-twitch response in rodents by 1977
Dose reported in human volunteers: 25 mg orally with nausea and no LSD-like effects
Embargoed record: doctoral thesis at Columbia University embargoed until 2030

- The paper lists a dose of 0.5 mg, annotated with a Latin mark indicating doubt.
- Quipazine was first synthesized and reported in 1966.
- By 1977, quipazine produced the head-twitch response in rodents, a marker of 5-HT2A activation.
- Human volunteers given 25 mg orally reported nausea, flatulence, gastrointestinal discomfort, and diarrhea with no psychedelic subjective effects.
- A 1994 theoretical proposal suggested an anti-nausea drug could enable human testing, but the proposed test appears only in an anonymous, unverified report and a Columbia thesis embargoed until 2030.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098247Wed, 22 Jul 2026 02:57:19 +0000Creator at Obomedia0.5 mg "sic" vs 400 mg aspirin; compound unnamed; human stakes: potential psychedelic/antidepressant but unconfirmed A single line in a paper flagged with a Latin mark calls out an impossible dose: half a milligram - one-eightieth the weight of an...
A single line in a paper flagged with a Latin mark calls out an impossible dose: half a milligram - one-eightieth the weight of an aspirin - and that unexplained number has haunted six decades of research into a drug that made rodents act like they'd taken LSD. How did a molecule that produced clear psychedelic-like effects in animals, yet caused uncontrollable vomiting and produced no psychedelic reports in humans at 25 mg, remain a pharmacological ghost in the literature?

In this episode, we trace the molecule’s arc from its first synthesis in 1966 through animal studies, receptor mapping, and the sparse human data, and we ask what stalled its path to clinical clarity - is the answer buried in an embargoed doctoral thesis or in the messy biology of serotonin receptors?

Person: quipazine
Date: first reported 1966
Event: registered head-twitch response in rodents by 1977
Dose reported in human volunteers: 25 mg orally with nausea and no LSD-like effects
Embargoed record: doctoral thesis at Columbia University embargoed until 2030

- The paper lists a dose of 0.5 mg, annotated with a Latin mark indicating doubt.
- Quipazine was first synthesized and reported in 1966.
- By 1977, quipazine produced the head-twitch response in rodents, a marker of 5-HT2A activation.
- Human volunteers given 25 mg orally reported nausea, flatulence, gastrointestinal discomfort, and diarrhea with no psychedelic subjective effects.
- A 1994 theoretical proposal suggested an anti-nausea drug could enable human testing, but the proposed test appears only in an anonymous, unverified report and a Columbia thesis embargoed until 2030.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1216falsefullhttps://www.spreaker.com/episode/a-sealed-doctoral-thesis-at-columbia-holds-quipazine-s-secrets-until-2030-unreadable-by-anyone--73098245
A single molecule can feel like a locked room: quipazine is chemically simple yet, for sixty years, it has produced both antidepressant-like signals and full psychedelic-like effects while also causing severe projectile vomiting in primates - and a doctoral thesis submitted to Columbia in August 2025 that no one may read until 2030 claims to hold new answers. What did that researcher find about quipazine’s double-edged pharmacology, and why was the work sealed for five years?

In this episode, we follow the episode’s recorded timeline and experiments to show what is documented about quipazine’s history, its behavioral effects in animal models, and the specific pharmacological puzzle that stopped its development, asking whether the sealed thesis finally resolves why quipazine both mimics LSD in drug discrimination tests and provokes unmanageable emesis.

Person: James Winter
Date: August 2025
Event: Thesis submission to Columbia University library system
Period: 1960s-1994 (research history described)
Topic: Quipazine dual-receptor activity (5-HT2A and 5-HT3)

- Quipazine is synthesized from two compounds: two-chloroquinoline and piperazine.
- The doctoral thesis was submitted in August 2025 and sealed until 2030.
- By 1971 quipazine had published data showing antidepressant-like effects in animal models.
- In rodent drug discrimination tests quipazine fully substituted for LSD.
- In primate studies quipazine produced reliable projectile vomiting linked to 5-HT3 activation.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098245Wed, 22 Jul 2026 02:57:07 +0000Creator at ObomediaA sealed doctoral thesis at Columbia holds quipazine's secrets until 2030 - unreadable by anyone A single molecule can feel like a locked room: quipazine is chemically simple yet, for sixty years, it has produced both antidepressant-like signals...
A single molecule can feel like a locked room: quipazine is chemically simple yet, for sixty years, it has produced both antidepressant-like signals and full psychedelic-like effects while also causing severe projectile vomiting in primates - and a doctoral thesis submitted to Columbia in August 2025 that no one may read until 2030 claims to hold new answers. What did that researcher find about quipazine’s double-edged pharmacology, and why was the work sealed for five years?

In this episode, we follow the episode’s recorded timeline and experiments to show what is documented about quipazine’s history, its behavioral effects in animal models, and the specific pharmacological puzzle that stopped its development, asking whether the sealed thesis finally resolves why quipazine both mimics LSD in drug discrimination tests and provokes unmanageable emesis.

Person: James Winter
Date: August 2025
Event: Thesis submission to Columbia University library system
Period: 1960s-1994 (research history described)
Topic: Quipazine dual-receptor activity (5-HT2A and 5-HT3)

- Quipazine is synthesized from two compounds: two-chloroquinoline and piperazine.
- The doctoral thesis was submitted in August 2025 and sealed until 2030.
- By 1971 quipazine had published data showing antidepressant-like effects in animal models.
- In rodent drug discrimination tests quipazine fully substituted for LSD.
- In primate studies quipazine produced reliable projectile vomiting linked to 5-HT3 activation.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1190falsefullhttps://www.spreaker.com/episode/a-40-year-obstacle-nausea-kept-a-potentially-novel-psychedelic-class-from-being-tested-in-humans--73098242
The idea that a single side effect could block a whole line of psychedelic discovery is chilling: quipazine produced clear LSD-like signals in rodents and monkeys yet caused uncontrollable nausea in primates and humans. How did a molecule described in 1966, active at five distinct serotonin receptors, point toward psychedelic potential for forty years and still fail to open the door for human testing?

In this episode, we tell the story of quipazine from its first synthesis to the human trials that halted its promise, tracing why animal models misled researchers and what the simultaneous emergence of psychedelic behavior and violent vomiting in primates meant for translational science. Could a receptor profile that looks psychedelic on paper be rendered moot by a single dominant physiological response?

Person: anonymous human subject in 2007
Date: 1966 (first appearance in literature)
Compound: one-(2-quinolinyl)piperazine (quipazine, 2-QP)
Receptor targets: 5-HT3 agonism plus activity at 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT1B
Dose in human trial: 25 mg orally

- Quipazine first appeared in the scientific literature in 1966 and was called one-(2-quinolinyl)piperazine (2-QP).
- In 1977, rodents dosed with quipazine displayed the head-twitch response, a reliable marker of 5-HT2A activation.
- Rodent drug-discrimination studies showed quipazine fully substituted for LSD, and LSD fully substituted for quipazine.
- Monkeys given quipazine showed LSD-like behavioral changes concurrently with projectile vomiting.
- Human subjects given 25 mg orally reported nausea, flatulence, gastrointestinal discomfort, and diarrhea with no perceptual alterations.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098242Wed, 22 Jul 2026 02:56:55 +0000Creator at ObomediaA 40-year obstacle (nausea) kept a potentially novel psychedelic class from being tested in humans The idea that a single side effect could block a whole line of psychedelic discovery is chilling: quipazine produced clear LSD-like signals in...
The idea that a single side effect could block a whole line of psychedelic discovery is chilling: quipazine produced clear LSD-like signals in rodents and monkeys yet caused uncontrollable nausea in primates and humans. How did a molecule described in 1966, active at five distinct serotonin receptors, point toward psychedelic potential for forty years and still fail to open the door for human testing?

In this episode, we tell the story of quipazine from its first synthesis to the human trials that halted its promise, tracing why animal models misled researchers and what the simultaneous emergence of psychedelic behavior and violent vomiting in primates meant for translational science. Could a receptor profile that looks psychedelic on paper be rendered moot by a single dominant physiological response?

Person: anonymous human subject in 2007
Date: 1966 (first appearance in literature)
Compound: one-(2-quinolinyl)piperazine (quipazine, 2-QP)
Receptor targets: 5-HT3 agonism plus activity at 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT1B
Dose in human trial: 25 mg orally

- Quipazine first appeared in the scientific literature in 1966 and was called one-(2-quinolinyl)piperazine (2-QP).
- In 1977, rodents dosed with quipazine displayed the head-twitch response, a reliable marker of 5-HT2A activation.
- Rodent drug-discrimination studies showed quipazine fully substituted for LSD, and LSD fully substituted for quipazine.
- Monkeys given quipazine showed LSD-like behavioral changes concurrently with projectile vomiting.
- Human subjects given 25 mg orally reported nausea, flatulence, gastrointestinal discomfort, and diarrhea with no perceptual alterations.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1188falsefullhttps://www.spreaker.com/episode/the-drug-that-made-animals-trip-humans-couldn-t-stomach-it--73098237
Quipazine produced head-twitches and full drug-discrimination substitution in rodents and monkeys, yet in humans even 25 mg caused vomiting and intolerable gastrointestinal distress-could a molecule that clearly acted like a psychedelic in animals ever be tested safely in people?

In this episode, we trace quipazine’s six-decade arc from a 1966 antidepressant candidate to a legal, unscheduled compound that elicited LSD-like signatures in animals but failed every human escalation; can the gap between animal signals and human tolerability be bridged?

Person: quipazine
Date: 1966 (first literature appearance)
Date: 1977 (head-twitch results reported)
Date: 2007 (single anonymous human account reported)
Date: August 2025 (Columbia thesis completed; embargoed until 2030)

- Quipazine’s full systematic name is one-(two-quinolinyl)piperazine (two-QP).
- Quipazine is a strong agonist at the 5-HT3 receptor and weaker agonist at 5-HT2A, 5-HT2B, and 5-HT2C.
- In 1977 quipazine produced the head-twitch response in mice and rats, blocked by the 5-HT2A antagonist ketanserin.
- Quipazine fully substituted for LSD in drug-discrimination studies in rodents and substituted for DOM in rodents and monkeys.
- A documented human dose of 25 mg orally produced nausea, flatulence, gastrointestinal discomfort, diarrhea and prevented escalation to psychedelic thresholds.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098237Wed, 22 Jul 2026 02:56:43 +0000Creator at ObomediaThe Drug That Made Animals Trip - Humans Couldn't Stomach It Quipazine produced head-twitches and full drug-discrimination substitution in rodents and monkeys, yet in humans even 25 mg caused vomiting and intolerable gastrointestinal distress-could...
Quipazine produced head-twitches and full drug-discrimination substitution in rodents and monkeys, yet in humans even 25 mg caused vomiting and intolerable gastrointestinal distress-could a molecule that clearly acted like a psychedelic in animals ever be tested safely in people?

In this episode, we trace quipazine’s six-decade arc from a 1966 antidepressant candidate to a legal, unscheduled compound that elicited LSD-like signatures in animals but failed every human escalation; can the gap between animal signals and human tolerability be bridged?

Person: quipazine
Date: 1966 (first literature appearance)
Date: 1977 (head-twitch results reported)
Date: 2007 (single anonymous human account reported)
Date: August 2025 (Columbia thesis completed; embargoed until 2030)

- Quipazine’s full systematic name is one-(two-quinolinyl)piperazine (two-QP).
- Quipazine is a strong agonist at the 5-HT3 receptor and weaker agonist at 5-HT2A, 5-HT2B, and 5-HT2C.
- In 1977 quipazine produced the head-twitch response in mice and rats, blocked by the 5-HT2A antagonist ketanserin.
- Quipazine fully substituted for LSD in drug-discrimination studies in rodents and substituted for DOM in rodents and monkeys.
- A documented human dose of 25 mg orally produced nausea, flatulence, gastrointestinal discomfort, diarrhea and prevented escalation to psychedelic thresholds.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1162falsefullhttps://www.spreaker.com/episode/the-compound-that-vomited-before-it-could-become-magic--73098234
A lone human report claims a full psychedelic response to quipazine, a molecule that triggered LSD-like effects in rodents and primates for 60 years yet produced almost exclusively severe nausea in human tests - so how close did science come to a psychedelic that the body refused to tolerate? What stopped researchers from separating its emetic action from its serotonin two-A effects?

In this episode, we lay out the history and data around quipazine across decades of literature, showing what animal models predicted and what the single human record actually reported - and ask whether the nausea and psychedelic action could ever have been disentangled.

Person: Jerrold C. Winter
Date (first literature appearance): 1966
Chemical name: one-(2-quinolinyl)piperazine
Dose (human test): 25 mg orally
Reported human effects: nausea, flatulence, gastrointestinal discomfort, diarrhea

- First published in the scientific literature in 1966 and described as antidepressant-like by 1971.
- In 1977, animal studies showed quipazine produced head-twitch responses linked to serotonin 2A receptor activation.
- Ketanserin blocked quipazine’s head-twitch response, tying its psychedelic-like action to the 5-HT2A receptor.
- Human administration of 25 mg produced nausea, flatulence, gastrointestinal discomfort and diarrhea with no reported LSD-like subjective effects.
- A contested anecdote reported 0.5 mg producing mild mescaline-like effects plus dysphoria and nausea, noted as likely erroneous in the scientific record.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098234Wed, 22 Jul 2026 02:56:31 +0000Creator at ObomediaThe Compound That Vomited Before It Could Become Magic A lone human report claims a full psychedelic response to quipazine, a molecule that triggered LSD-like effects in rodents and primates for 60 years yet produced almost exclusively severe...
A lone human report claims a full psychedelic response to quipazine, a molecule that triggered LSD-like effects in rodents and primates for 60 years yet produced almost exclusively severe nausea in human tests - so how close did science come to a psychedelic that the body refused to tolerate? What stopped researchers from separating its emetic action from its serotonin two-A effects?

In this episode, we lay out the history and data around quipazine across decades of literature, showing what animal models predicted and what the single human record actually reported - and ask whether the nausea and psychedelic action could ever have been disentangled.

Person: Jerrold C. Winter
Date (first literature appearance): 1966
Chemical name: one-(2-quinolinyl)piperazine
Dose (human test): 25 mg orally
Reported human effects: nausea, flatulence, gastrointestinal discomfort, diarrhea

- First published in the scientific literature in 1966 and described as antidepressant-like by 1971.
- In 1977, animal studies showed quipazine produced head-twitch responses linked to serotonin 2A receptor activation.
- Ketanserin blocked quipazine’s head-twitch response, tying its psychedelic-like action to the 5-HT2A receptor.
- Human administration of 25 mg produced nausea, flatulence, gastrointestinal discomfort and diarrhea with no reported LSD-like subjective effects.
- A contested anecdote reported 0.5 mg producing mild mescaline-like effects plus dysphoria and nausea, noted as likely erroneous in the scientific record.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1241falsefullhttps://www.spreaker.com/episode/the-molecule-that-should-have-been-a-psychedelic-but-broke-researchers-stomachs--73098231
Half a milligram supposedly produced mescaline-like effects, but the same compound triggered dysphoria and relentless nausea instead; why did a molecule that activated classic psychedelic receptors become defined by stomach-upsetting side effects? What happened to quipazine between a 1966 synthesis and a thesis sealed until 2030?

In this episode, we trace quipazine’s fifty-year scientific arc from a 1966 arylpiperazine synthesis to animal and fragmentary human reports, and ask whether its mixed pharmacology doomed its clinical promise or simply redirected research toward its derivatives.

Person: quipazine (one-parenthesis-two-quinolinyl-parenthesis-piperazine)
Date: 1966 (synthesis)
Event: head-twitch response in rodents starting 1977
Receptor: primary agonism at 5-HT3 and agonism at 5-HT2A/2B/2C
Status: doctoral thesis on descendants embargoed until 2030

- Reported human dose anomaly: half a milligram claimed to produce low-dose mescaline-like effects, flagged with “sic.”
- Animal behavioral finding: quipazine produced a rapid, involuntary head-twitch response in mice, rats, and monkeys.
- Receptor-specific evidence: ketanserin blockade abolished quipazine-induced head-twitch response, implicating 5-HT2A activation.
- Pharmacological profile: notable potency at 5-HT3 plus agonism at 5-HT2A, 2B, 2C, inhibition of serotonin reuptake, and affinity at 5-HT1B and dopamine receptors.
- Archive detail: a 2025 doctoral thesis with the most detailed recent analysis of quipazine’s descendants is embargoed and sealed until 2030.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098231Wed, 22 Jul 2026 02:56:18 +0000Creator at ObomediaThe Molecule That Should Have Been a Psychedelic - But Broke Researchers' Stomachs Half a milligram supposedly produced mescaline-like effects, but the same compound triggered dysphoria and relentless nausea instead; why did a molecule that...
Half a milligram supposedly produced mescaline-like effects, but the same compound triggered dysphoria and relentless nausea instead; why did a molecule that activated classic psychedelic receptors become defined by stomach-upsetting side effects? What happened to quipazine between a 1966 synthesis and a thesis sealed until 2030?

In this episode, we trace quipazine’s fifty-year scientific arc from a 1966 arylpiperazine synthesis to animal and fragmentary human reports, and ask whether its mixed pharmacology doomed its clinical promise or simply redirected research toward its derivatives.

Person: quipazine (one-parenthesis-two-quinolinyl-parenthesis-piperazine)
Date: 1966 (synthesis)
Event: head-twitch response in rodents starting 1977
Receptor: primary agonism at 5-HT3 and agonism at 5-HT2A/2B/2C
Status: doctoral thesis on descendants embargoed until 2030

- Reported human dose anomaly: half a milligram claimed to produce low-dose mescaline-like effects, flagged with “sic.”
- Animal behavioral finding: quipazine produced a rapid, involuntary head-twitch response in mice, rats, and monkeys.
- Receptor-specific evidence: ketanserin blockade abolished quipazine-induced head-twitch response, implicating 5-HT2A activation.
- Pharmacological profile: notable potency at 5-HT3 plus agonism at 5-HT2A, 2B, 2C, inhibition of serotonin reuptake, and affinity at 5-HT1B and dopamine receptors.
- Archive detail: a 2025 doctoral thesis with the most detailed recent analysis of quipazine’s descendants is embargoed and sealed until 2030.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1136falsefullhttps://www.spreaker.com/episode/the-drug-that-turned-champions-into-cancer-labs--73098229
A drug abandoned by its maker for causing cancer in rodents reappeared years later as a performance miracle for athletes - and by 2011 it was selling on the black market for $1,000 per 10 grams. How did a compound with no approved human dose, hidden toxicity data, and links to multi-organ cancer end up in the bloodstream of champions across continents?

In this episode, we trace the compound's journey from GlaxoSmithKline and Ligand's lab work in 1992 through clinical trials and quiet abandonment in 2007, to Salk Institute research that revealed dramatic endurance gains and to its spread into professional sport. What sequence of discoveries, publications, and market forces turned a shelved pharmaceutical into a banned athletic drug?

Person: Ronald M. Evans
Date: 1992
Location: Salk Institute, California
Event: World Anti-Doping Agency ban in 2009
Topic: GW501516 (PPARδ agonist)

- GW501516 was first synthesized by GlaxoSmithKline and Ligand Pharmaceuticals in 1992.
- At 3 mg/kg/day, mice and rats developed rapid, multi-organ cancer during preclinical studies.
- Phase one and phase two human trials ran in 2000-2003, with program abandonment by GSK in 2007.
- Salk Institute published 2007 Cell papers showing dramatic increases in mice endurance via PGC-1α recruitment.
- By 2011 GW501516 sold on the black market for $1,000 per 10 grams and athletes in at least five sports across four continents tested positive.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098229Wed, 22 Jul 2026 02:56:07 +0000Creator at ObomediaThe Drug That Turned Champions Into Cancer Labs A drug abandoned by its maker for causing cancer in rodents reappeared years later as a performance miracle for athletes - and by 2011 it was selling on the black market for $1,000 per 10 grams. How...
A drug abandoned by its maker for causing cancer in rodents reappeared years later as a performance miracle for athletes - and by 2011 it was selling on the black market for $1,000 per 10 grams. How did a compound with no approved human dose, hidden toxicity data, and links to multi-organ cancer end up in the bloodstream of champions across continents?

In this episode, we trace the compound's journey from GlaxoSmithKline and Ligand's lab work in 1992 through clinical trials and quiet abandonment in 2007, to Salk Institute research that revealed dramatic endurance gains and to its spread into professional sport. What sequence of discoveries, publications, and market forces turned a shelved pharmaceutical into a banned athletic drug?

Person: Ronald M. Evans
Date: 1992
Location: Salk Institute, California
Event: World Anti-Doping Agency ban in 2009
Topic: GW501516 (PPARδ agonist)

- GW501516 was first synthesized by GlaxoSmithKline and Ligand Pharmaceuticals in 1992.
- At 3 mg/kg/day, mice and rats developed rapid, multi-organ cancer during preclinical studies.
- Phase one and phase two human trials ran in 2000-2003, with program abandonment by GSK in 2007.
- Salk Institute published 2007 Cell papers showing dramatic increases in mice endurance via PGC-1α recruitment.
- By 2011 GW501516 sold on the black market for $1,000 per 10 grams and athletes in at least five sports across four continents tested positive.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1123falsefullhttps://www.spreaker.com/episode/the-drug-that-made-champions-and-grew-tumors-in-mice--73098227
A single molecule could turn a human into an endurance machine while triggering rapid, multi-organ cancer in rodents; GW501516 was developed by a major pharmaceutical company, tested on human volunteers, and abandoned after animal studies showed tumors - so how did it become a black-market performance enhancer anyway?

In this episode, we tell the sequence of events from the lab bench to elite sport, showing the compound's development, clinical testing, abandoned program, and later high-profile endurance studies - and we ask how a cancer-flagged drug circulated to athletes without public warning.

Person: GlaxoSmithKline
Date: 2007
Location: Salk Institute
Topic: GW501516 / PPARδ agonist
Event: Phase I and II human trials completed

- GW501516 was first developed in 1992 in a collaboration between GlaxoSmithKline and Ligand Pharmaceuticals.
- Its potency was approximately 1 nanomolar and selectivity greater than 1,000-fold.
- Two phase two clinical studies had been completed by 2007 with human volunteers.
- Animal studies showed rapid multi-organ cancer in mice and rats at 3 mg/kg/day.
- Ronald M. Evans's Salk Institute study reported dramatic increases in endurance in mice using higher doses and was published in Cell.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098227Wed, 22 Jul 2026 02:55:55 +0000Creator at ObomediaThe Drug That Made Champions - and Grew Tumors in Mice A single molecule could turn a human into an endurance machine while triggering rapid, multi-organ cancer in rodents; GW501516 was developed by a major pharmaceutical company, tested on human...
A single molecule could turn a human into an endurance machine while triggering rapid, multi-organ cancer in rodents; GW501516 was developed by a major pharmaceutical company, tested on human volunteers, and abandoned after animal studies showed tumors - so how did it become a black-market performance enhancer anyway?

In this episode, we tell the sequence of events from the lab bench to elite sport, showing the compound's development, clinical testing, abandoned program, and later high-profile endurance studies - and we ask how a cancer-flagged drug circulated to athletes without public warning.

Person: GlaxoSmithKline
Date: 2007
Location: Salk Institute
Topic: GW501516 / PPARδ agonist
Event: Phase I and II human trials completed

- GW501516 was first developed in 1992 in a collaboration between GlaxoSmithKline and Ligand Pharmaceuticals.
- Its potency was approximately 1 nanomolar and selectivity greater than 1,000-fold.
- Two phase two clinical studies had been completed by 2007 with human volunteers.
- Animal studies showed rapid multi-organ cancer in mice and rats at 3 mg/kg/day.
- Ronald M. Evans's Salk Institute study reported dramatic increases in endurance in mice using higher doses and was published in Cell.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1287falsefullhttps://www.spreaker.com/episode/the-abandoned-mushroom-drug-that-perfected-deep-sleep-and-vanished--73098221
A single compound increased slow-wave sleep dramatically while matching morphine's pain relief without causing respiratory depression-yet it was abandoned twice. Derived conceptually from muscimol in Amanita muscaria and engineered as THIP/gaboxadol, it targeted a distinct delta-containing GABA-A receptor that mediates tonic inhibition; why did a drug that deepened restorative sleep and avoided typical sedative harms disappear from the clinic?

In this episode, we trace the documented history of gaboxadol: its chemical origins from work in the 1970s, early human trials across chronic pain, spasticity, anxiety and Huntington's disease, and the 1996 findings showing increased slow-wave sleep-so how did a molecule with such unique effects get set aside?

Person: Povl Krogsgaard-Larsen
Person: Alf Lancel
Event: Early human trials in the 1970s and early 1980s
Date: 1996 (publication of gaboxadol sleep results)
Compound: THIP (gaboxadol; 4,5,6,7-tetrahydroisoxazolo-pyridinol-3-ol)

- Gaboxadol was synthesized from insights about muscimol, the active agent in Amanita muscaria.
- Early trials in the 1970s and early 1980s tested gaboxadol for chronic pain, spasticity, anxiety, and Huntington's disease.
- Gaboxadol acts on GABA-A receptors containing the delta subunit, mediating tonic inhibition rather than synaptic phasic inhibition.
- The drug matched morphine's painkilling power without triggering respiratory depression, according to the transcript.
- In 1996 Alf Lancel reported that gaboxadol dramatically increased the duration and depth of slow-wave sleep in healthy volunteers.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098221Wed, 22 Jul 2026 02:55:43 +0000Creator at ObomediaThe Abandoned Mushroom Drug That Perfected Deep Sleep-and Vanished A single compound increased slow-wave sleep dramatically while matching morphine's pain relief without causing respiratory depression-yet it was abandoned twice. Derived...
A single compound increased slow-wave sleep dramatically while matching morphine's pain relief without causing respiratory depression-yet it was abandoned twice. Derived conceptually from muscimol in Amanita muscaria and engineered as THIP/gaboxadol, it targeted a distinct delta-containing GABA-A receptor that mediates tonic inhibition; why did a drug that deepened restorative sleep and avoided typical sedative harms disappear from the clinic?

In this episode, we trace the documented history of gaboxadol: its chemical origins from work in the 1970s, early human trials across chronic pain, spasticity, anxiety and Huntington's disease, and the 1996 findings showing increased slow-wave sleep-so how did a molecule with such unique effects get set aside?

Person: Povl Krogsgaard-Larsen
Person: Alf Lancel
Event: Early human trials in the 1970s and early 1980s
Date: 1996 (publication of gaboxadol sleep results)
Compound: THIP (gaboxadol; 4,5,6,7-tetrahydroisoxazolo-pyridinol-3-ol)

- Gaboxadol was synthesized from insights about muscimol, the active agent in Amanita muscaria.
- Early trials in the 1970s and early 1980s tested gaboxadol for chronic pain, spasticity, anxiety, and Huntington's disease.
- Gaboxadol acts on GABA-A receptors containing the delta subunit, mediating tonic inhibition rather than synaptic phasic inhibition.
- The drug matched morphine's painkilling power without triggering respiratory depression, according to the transcript.
- In 1996 Alf Lancel reported that gaboxadol dramatically increased the duration and depth of slow-wave sleep in healthy volunteers.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1185falsefullhttps://www.spreaker.com/episode/the-strange-rise-and-vanishing-of-urine-derived-estrone-treatments--73098218
Pregnancy urine became a pharmaceutical goldmine: by 1929 crystalline estrone was purified from pregnant women's urine and sold worldwide under names like Theelin and Progynon - yet estrone binds the estrogen receptor at only about 4% of estradiol's strength. How did a molecule so weak produce clear clinical reversals of surgical menopause, then disappear from most markets?

In this episode, we tell the story of how estrone moved from a 1927 discovery in a Berlin lab to a global medical product, the documented clinical successes in ovariectomized women, and the unresolved contradiction between clinical effect and receptor data. What hidden process explained the results that estrone itself could not?

Person: Bernhard Zondek and Selmar Aschheim
Date: 1927-1929
Location: Berlin; Europe and North America
Event: Purification and sale of crystalline estrone from pregnancy urine
Topic: Clinical use of estrone in ovariectomized women

- In 1927 researchers in Berlin discovered large quantities of estrogenic substances in pregnancy urine.
- By 1929 three manufacturers (Parke‑Davis, Schering, Squibb) were selling crystalline estrone as Theelin, Progynon, and Amniotin.
- Clinical trials in the 1930s recorded reversal of vaginal atrophy and reduction of vasomotor symptoms in ovariectomized women after estrone injections.
- Estrone's binding affinity to the estrogen receptor measured roughly 4% of estradiol's binding strength.
- Multiple companies (Abbott, Lilly, British Drug Houses, Organon, Paines and Byrne) marketed estrone products under different names across Europe, North America, and Asia.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098218Wed, 22 Jul 2026 02:55:30 +0000Creator at ObomediaThe Strange Rise and Vanishing of Urine‑Derived Estrone Treatments Pregnancy urine became a pharmaceutical goldmine: by 1929 crystalline estrone was purified from pregnant women's urine and sold worldwide under names like Theelin and Progynon - yet...
Pregnancy urine became a pharmaceutical goldmine: by 1929 crystalline estrone was purified from pregnant women's urine and sold worldwide under names like Theelin and Progynon - yet estrone binds the estrogen receptor at only about 4% of estradiol's strength. How did a molecule so weak produce clear clinical reversals of surgical menopause, then disappear from most markets?

In this episode, we tell the story of how estrone moved from a 1927 discovery in a Berlin lab to a global medical product, the documented clinical successes in ovariectomized women, and the unresolved contradiction between clinical effect and receptor data. What hidden process explained the results that estrone itself could not?

Person: Bernhard Zondek and Selmar Aschheim
Date: 1927-1929
Location: Berlin; Europe and North America
Event: Purification and sale of crystalline estrone from pregnancy urine
Topic: Clinical use of estrone in ovariectomized women

- In 1927 researchers in Berlin discovered large quantities of estrogenic substances in pregnancy urine.
- By 1929 three manufacturers (Parke‑Davis, Schering, Squibb) were selling crystalline estrone as Theelin, Progynon, and Amniotin.
- Clinical trials in the 1930s recorded reversal of vaginal atrophy and reduction of vasomotor symptoms in ovariectomized women after estrone injections.
- Estrone's binding affinity to the estrogen receptor measured roughly 4% of estradiol's binding strength.
- Multiple companies (Abbott, Lilly, British Drug Houses, Organon, Paines and Byrne) marketed estrone products under different names across Europe, North America, and Asia.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1129falsefullhttps://www.spreaker.com/episode/the-slow-release-drug-that-killed-healthy-hearts-one-injection-at-a-time--73098216
A slow-release estrogen injection raised estradiol in healthy men nearly seventeenfold within ninety days and left 16 of 21 developing cardiovascular complications despite pre-trial screening for heart disease. Which chemical design decision turned a therapeutic advantage-months-long dosing from a single injection-into a hidden cardiovascular hazard?

In this episode, we trace the molecule’s journey from a 1953 chemist’s paper to clinical use in 1956 and its role across indications, closing on the Mainz trial where men with advanced prostate cancer received monthly injections and unexpected vascular harm emerged. How did estradiol undecylate’s depot chemistry, dosage choices, and clinical uses conspire to produce those outcomes?

Person: Karl Junkmann
Date: 1953
Location: Mainz, Germany
Trial: Jacobi study (phase three multicenter randomized controlled trial)
Dose range: 10-12.5 mg (40-60 days), 25-50 mg (2-4 months), 100 mg/month (prostate cancer studies)

- One injection of 10-12.5 mg remained active for 40-60 days due to depot formation in muscle.
- A single 100 mg/month regimen reduced testosterone from ~416 ng/dL to 38 ng/dL at three months (93% reduction).
- In the Mainz subgroup estradiol rose from 36 pg/mL baseline to 486 pg/mL at three months and 598 pg/mL at six months (≈17× increase).
- The Jacobi trial enrolled 191 patients across 12 centers and ran for six months comparing estradiol undecylate to cyproterone acetate.
- Sixteen of twenty-one men in the Mainz subgroup developed cardiovascular complications despite being screened as free of prior heart disease.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098216Wed, 22 Jul 2026 02:55:19 +0000Creator at ObomediaThe Slow-Release Drug That Killed Healthy Hearts, One Injection at a Time A slow-release estrogen injection raised estradiol in healthy men nearly seventeenfold within ninety days and left 16 of 21 developing cardiovascular complications despite...
A slow-release estrogen injection raised estradiol in healthy men nearly seventeenfold within ninety days and left 16 of 21 developing cardiovascular complications despite pre-trial screening for heart disease. Which chemical design decision turned a therapeutic advantage-months-long dosing from a single injection-into a hidden cardiovascular hazard?

In this episode, we trace the molecule’s journey from a 1953 chemist’s paper to clinical use in 1956 and its role across indications, closing on the Mainz trial where men with advanced prostate cancer received monthly injections and unexpected vascular harm emerged. How did estradiol undecylate’s depot chemistry, dosage choices, and clinical uses conspire to produce those outcomes?

Person: Karl Junkmann
Date: 1953
Location: Mainz, Germany
Trial: Jacobi study (phase three multicenter randomized controlled trial)
Dose range: 10-12.5 mg (40-60 days), 25-50 mg (2-4 months), 100 mg/month (prostate cancer studies)

- One injection of 10-12.5 mg remained active for 40-60 days due to depot formation in muscle.
- A single 100 mg/month regimen reduced testosterone from ~416 ng/dL to 38 ng/dL at three months (93% reduction).
- In the Mainz subgroup estradiol rose from 36 pg/mL baseline to 486 pg/mL at three months and 598 pg/mL at six months (≈17× increase).
- The Jacobi trial enrolled 191 patients across 12 centers and ran for six months comparing estradiol undecylate to cyproterone acetate.
- Sixteen of twenty-one men in the Mainz subgroup developed cardiovascular complications despite being screened as free of prior heart disease.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1200falsefullhttps://www.spreaker.com/episode/the-one-injection-that-silenced-hearts-the-long-acting-estrogen-tragedy--73098198
A single 100 mg oil-suspended injection promised up to four months of estradiol release, yet a clinical trial reported 76% cardiovascular complications and two deaths in one arm-what went wrong with a drug once hailed as elegant? How did a molecule designed to cling to fat and release predictably become lethal to the heart?

In this episode, we lay out the clinical record, patents, and trial data that chart estradiol undecylate’s rise from 1953 chemistry to worldwide use and its catastrophic trial results-what does the Mainz trial reveal about the risks of long-acting estrogens?

Person: Karl Junkmann
Date: 1953 (description of estradiol undecylate)
Location: University of Mainz (trial site)
Status: No longer manufactured anywhere in the world
Topic: Estradiol undecylate clinical use and trial outcomes

- One injection contained 100 milligrams of estradiol undecylate suspended in oil.
- The compound could release estrogen into the bloodstream for up to four months from a single dose.
- In the Mainz trial, 76% of men in one treatment arm suffered cardiovascular complications.
- Two participants in that treatment arm died.
- Women with breast cancer were treated with doses of 200 mg injected three times per week, totaling roughly 2400 mg per month.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098198Wed, 22 Jul 2026 02:55:07 +0000Creator at ObomediaThe One Injection That Silenced Hearts: The Long‑Acting Estrogen Tragedy A single 100 mg oil-suspended injection promised up to four months of estradiol release, yet a clinical trial reported 76% cardiovascular complications and two deaths in one...
A single 100 mg oil-suspended injection promised up to four months of estradiol release, yet a clinical trial reported 76% cardiovascular complications and two deaths in one arm-what went wrong with a drug once hailed as elegant? How did a molecule designed to cling to fat and release predictably become lethal to the heart?

In this episode, we lay out the clinical record, patents, and trial data that chart estradiol undecylate’s rise from 1953 chemistry to worldwide use and its catastrophic trial results-what does the Mainz trial reveal about the risks of long-acting estrogens?

Person: Karl Junkmann
Date: 1953 (description of estradiol undecylate)
Location: University of Mainz (trial site)
Status: No longer manufactured anywhere in the world
Topic: Estradiol undecylate clinical use and trial outcomes

- One injection contained 100 milligrams of estradiol undecylate suspended in oil.
- The compound could release estrogen into the bloodstream for up to four months from a single dose.
- In the Mainz trial, 76% of men in one treatment arm suffered cardiovascular complications.
- Two participants in that treatment arm died.
- Women with breast cancer were treated with doses of 200 mg injected three times per week, totaling roughly 2400 mg per month.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1333falsefullhttps://www.spreaker.com/episode/the-tiny-frog-that-almost-rewrote-pain-medicine-and-vanished--73098194
A tiny Ecuadorian frog carried less than one milligram of a compound more than 200 times as potent as morphine, non‑addictive in effect, and possibly capable of changing pain medicine - yet science still cannot confirm the substance’s molecular identity. How did three thousand collected frog skins yield a pharmacological miracle that vanished into a chemical ghost, and what stopped it from becoming a drug?

In this episode, we trace the fieldwork, laboratory struggles, and legal and ecological limits that shaped the discovery and disappearance of epibatidine. We follow John W. Daly’s decades-long path from forest collections to mouse analgesia tests, and ask whether the promise locked on a frog’s skin could ever have been realized.

Person: John W. Daly
Species: Epipedobates anthonyi
Compound: epibatidine (unconfirmed molecular structure)
Total extract recovered: less than 1 milligram
Fieldwork span: 1974-1979

- Daly and colleague Charles Myers processed approximately 3,000 frog skins across multiple Ecuador sites.
- Initial skin preparations injected into mice produced clear, reproducible opioid-like analgesia.
- The compound observed was reported as over 200 times as potent as morphine and described as non‑addictive in action.
- In 1976, frogs from one collection site produced zero analgesic effect, indicating the compound depended on diet.
- By 1984 Epipedobates anthonyi received protected IUCN status, severely restricting further wild collection.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098194Wed, 22 Jul 2026 02:54:55 +0000Creator at ObomediaThe Tiny Frog That Almost Rewrote Pain Medicine-and Vanished A tiny Ecuadorian frog carried less than one milligram of a compound more than 200 times as potent as morphine, non‑addictive in effect, and possibly capable of changing pain medicine -...
A tiny Ecuadorian frog carried less than one milligram of a compound more than 200 times as potent as morphine, non‑addictive in effect, and possibly capable of changing pain medicine - yet science still cannot confirm the substance’s molecular identity. How did three thousand collected frog skins yield a pharmacological miracle that vanished into a chemical ghost, and what stopped it from becoming a drug?

In this episode, we trace the fieldwork, laboratory struggles, and legal and ecological limits that shaped the discovery and disappearance of epibatidine. We follow John W. Daly’s decades-long path from forest collections to mouse analgesia tests, and ask whether the promise locked on a frog’s skin could ever have been realized.

Person: John W. Daly
Species: Epipedobates anthonyi
Compound: epibatidine (unconfirmed molecular structure)
Total extract recovered: less than 1 milligram
Fieldwork span: 1974-1979

- Daly and colleague Charles Myers processed approximately 3,000 frog skins across multiple Ecuador sites.
- Initial skin preparations injected into mice produced clear, reproducible opioid-like analgesia.
- The compound observed was reported as over 200 times as potent as morphine and described as non‑addictive in action.
- In 1976, frogs from one collection site produced zero analgesic effect, indicating the compound depended on diet.
- By 1984 Epipedobates anthonyi received protected IUCN status, severely restricting further wild collection.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1220falsefullhttps://www.spreaker.com/episode/the-vial-that-vanished-the-painkiller-hidden-in-a-grain-of-dust--73098192
The smallest residue in a glass vial-less than one milligram, smaller than a grain of salt-might be the only remaining trace of a natural painkiller up to 2,900 times more potent than morphine. If the frogs never produced it themselves but accumulated it from their diet, then every milligram ever extracted came from a finite wild harvest-so what really lived in that vial, and did it ever exist in nature at all?

In this episode, we follow the timeline from John W. Daly's 1974 fieldwork in Ecuador to the last fragile sample in 1991, tracing how a compound named epibatidine moved from amphibian skins to laboratory vials and into scientific controversy, and asking whether the molecule could be recreated or was lost to environmental circumstance.

Person: John W. Daly
Location: Ecuador
Species: Epipedobates anthonyi
Period: 1974-1991
Event: Less than 1 milligram remaining in 1991 vial

- Approximately 3,000 frog skins were collected across Ecuador between 1974 and 1979.
- Epibatidine showed analgesic efficacy measured as about 2,900 times greater than morphine in one rodent study.
- A more conservative potency estimate placed epibatidine at about 200 times the strength of morphine.
- In 1976, frogs from one collection site produced no epibatidine, indicating dietary acquisition rather than endogenous production.
- By 1984 the IUCN had moved to protect the species, effectively halting large-scale collection and fixing natural supply.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098192Wed, 22 Jul 2026 02:54:42 +0000Creator at ObomediaThe Vial That Vanished: The Painkiller Hidden in a Grain of Dust The smallest residue in a glass vial-less than one milligram, smaller than a grain of salt-might be the only remaining trace of a natural painkiller up to 2,900 times more potent than...
The smallest residue in a glass vial-less than one milligram, smaller than a grain of salt-might be the only remaining trace of a natural painkiller up to 2,900 times more potent than morphine. If the frogs never produced it themselves but accumulated it from their diet, then every milligram ever extracted came from a finite wild harvest-so what really lived in that vial, and did it ever exist in nature at all?

In this episode, we follow the timeline from John W. Daly's 1974 fieldwork in Ecuador to the last fragile sample in 1991, tracing how a compound named epibatidine moved from amphibian skins to laboratory vials and into scientific controversy, and asking whether the molecule could be recreated or was lost to environmental circumstance.

Person: John W. Daly
Location: Ecuador
Species: Epipedobates anthonyi
Period: 1974-1991
Event: Less than 1 milligram remaining in 1991 vial

- Approximately 3,000 frog skins were collected across Ecuador between 1974 and 1979.
- Epibatidine showed analgesic efficacy measured as about 2,900 times greater than morphine in one rodent study.
- A more conservative potency estimate placed epibatidine at about 200 times the strength of morphine.
- In 1976, frogs from one collection site produced no epibatidine, indicating dietary acquisition rather than endogenous production.
- By 1984 the IUCN had moved to protect the species, effectively halting large-scale collection and fixing natural supply.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1098falsefullhttps://www.spreaker.com/episode/how-a-perfectly-safe-drug-became-america-s-most-forbidden-molecule--73098190
A single chemist's small molecular tweak produced a compound that never failed a clinical safety test yet was placed on the United States' most restricted roster in February 1973 - how did that happen, and who decided the science no longer mattered? This episode traces DOET from Alexander Shulgin's lab notes and three favorable peer-reviewed trials to a vanished patent and a legal collapse that derailed its development.

In this episode, we follow the timeline of DOET's discovery, the institutional research path at Dow and Johns Hopkins, and the external events that altered the social and legal landscape for related compounds, asking how nonclinical events overturned clinical promise.

Person: Alexander Shulgin
Person: Solomon H. Snyder
Date: February 1973
Date: 1966 (patent filing for DOET)
Event: Distribution of DOM as STP in summer 1967

- Shulgin synthesized DOM in 1963 and confirmed its psychedelic effects by self-testing in 1964.
- In 1966 Dow filed a patent for DOET and described its potential pharmaceutical applications.
- Three peer-reviewed human trials on DOET returned favorable results with no documented clinical harms.
- LSD was made illegal in California in 1966, the same year DOET's patent was filed.
- In summer 1967 Owsley Stanley distributed DOM as STP at doses two to three times higher than clinical levels.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098190Wed, 22 Jul 2026 02:54:31 +0000Creator at ObomediaHow a Perfectly Safe Drug Became America's Most Forbidden Molecule A single chemist's small molecular tweak produced a compound that never failed a clinical safety test yet was placed on the United States' most restricted roster in February 1973 -...
A single chemist's small molecular tweak produced a compound that never failed a clinical safety test yet was placed on the United States' most restricted roster in February 1973 - how did that happen, and who decided the science no longer mattered? This episode traces DOET from Alexander Shulgin's lab notes and three favorable peer-reviewed trials to a vanished patent and a legal collapse that derailed its development.

In this episode, we follow the timeline of DOET's discovery, the institutional research path at Dow and Johns Hopkins, and the external events that altered the social and legal landscape for related compounds, asking how nonclinical events overturned clinical promise.

Person: Alexander Shulgin
Person: Solomon H. Snyder
Date: February 1973
Date: 1966 (patent filing for DOET)
Event: Distribution of DOM as STP in summer 1967

- Shulgin synthesized DOM in 1963 and confirmed its psychedelic effects by self-testing in 1964.
- In 1966 Dow filed a patent for DOET and described its potential pharmaceutical applications.
- Three peer-reviewed human trials on DOET returned favorable results with no documented clinical harms.
- LSD was made illegal in California in 1966, the same year DOET's patent was filed.
- In summer 1967 Owsley Stanley distributed DOM as STP at doses two to three times higher than clinical levels.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1283falsefullhttps://www.spreaker.com/episode/the-molecule-that-should-have-been-a-medicine-then-vanished--73098188
A molecule tested at Johns Hopkins showed no open‑eyed hallucinations across three published trials, yet it was scheduled as a controlled substance before the final paper appeared - how did a compound that seemed safer than other psychedelics disappear from development? This episode traces the unlikely arc from a Dow chemist’s laboratory to the streets of San Francisco and asks: which decisions - legal, personal, or accidental - truly ended this drug's future?

In this episode, we lay out the chronological facts behind the compound's discovery, early human testing, corporate development, and abrupt regulatory fate, following the people and events that intersected with that history and asking how the science and the law came to such different conclusions.

Person: Alexander Shulgin
Person: Solomon Snyder
Date: 1963 (synthesis of DOM); 1964 (discovery of DOM effects); 1965 (Dow selected DOET for development); 1966 (patent filed; LSD illegal in California)
Location: Johns Hopkins University (clinical trials); Dow Chemical (research)
Event: Publication of three trials showing no open‑eyed hallucinations; scheduling before third trial printed

- Shulgin synthesized DOM in 1963 and altered its 4‑position methyl group to an ethyl to create DOET.
- Shulgin self‑administered DOET and reported mood brightening and sharpened attention without hallucinations at low doses.
- A colleague given approximately the same dose reported profound lethargy and depression, documenting individual variability.
- Dow selected DOET for clinical development and assigned trials to Solomon Snyder around 1965.
- The compound was scheduled as a dangerous controlled substance before the third published trial had appeared; the patent appeared in 1970.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098188Wed, 22 Jul 2026 02:54:19 +0000Creator at ObomediaThe Molecule That Should Have Been a Medicine - Then Vanished A molecule tested at Johns Hopkins showed no open‑eyed hallucinations across three published trials, yet it was scheduled as a controlled substance before the final paper appeared - how...
A molecule tested at Johns Hopkins showed no open‑eyed hallucinations across three published trials, yet it was scheduled as a controlled substance before the final paper appeared - how did a compound that seemed safer than other psychedelics disappear from development? This episode traces the unlikely arc from a Dow chemist’s laboratory to the streets of San Francisco and asks: which decisions - legal, personal, or accidental - truly ended this drug's future?

In this episode, we lay out the chronological facts behind the compound's discovery, early human testing, corporate development, and abrupt regulatory fate, following the people and events that intersected with that history and asking how the science and the law came to such different conclusions.

Person: Alexander Shulgin
Person: Solomon Snyder
Date: 1963 (synthesis of DOM); 1964 (discovery of DOM effects); 1965 (Dow selected DOET for development); 1966 (patent filed; LSD illegal in California)
Location: Johns Hopkins University (clinical trials); Dow Chemical (research)
Event: Publication of three trials showing no open‑eyed hallucinations; scheduling before third trial printed

- Shulgin synthesized DOM in 1963 and altered its 4‑position methyl group to an ethyl to create DOET.
- Shulgin self‑administered DOET and reported mood brightening and sharpened attention without hallucinations at low doses.
- A colleague given approximately the same dose reported profound lethargy and depression, documenting individual variability.
- Dow selected DOET for clinical development and assigned trials to Solomon Snyder around 1965.
- The compound was scheduled as a dangerous controlled substance before the third published trial had appeared; the patent appeared in 1970.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1355falsefullhttps://www.spreaker.com/episode/when-a-street-panic-silenced-a-potential-psychedelic-medicine--73098184
A single corporate decision erased a patent for a compound that promised antidepressant effects without hallucinations. DOET, nicknamed Hecate, showed a therapeutic window estimated at five-fold or greater and produced no open-eye hallucinations in controlled tests - so why was it abandoned before it could become medicine?

In this episode, we trace the timeline from a 1966 patent filing through company withdrawal and a 1968 Johns Hopkins trial, asking how external social panic over a related street drug redirected scientific progress. What happened between bench notes and boardroom memos that ended DOET’s chances?

Person: Alexander Shulgin
Organization: Dow Chemical
Person: Solomon Snyder
Date: 1966
Date: 1968

- DOET (Hecate) patent filed by Dow Chemical in 1966.
- Shulgin estimated DOET’s therapeutic window at five-fold or greater compared to LSD and DOM’s two-to-three-fold.
- Johns Hopkins trial published in 1968 used 1.5 mg DOET hydrochloride orally.
- Reported onset in trial: 1 to 1.5 hours; peak duration: 3 to 4 hours; total resolution: 5 to 6 hours.
- Dow terminated the DOET program in 1968 after public crises linked to high-dose DOM (STP) in San Francisco.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098184Wed, 22 Jul 2026 02:54:07 +0000Creator at ObomediaWhen a Street Panic Silenced a Potential Psychedelic Medicine A single corporate decision erased a patent for a compound that promised antidepressant effects without hallucinations. DOET, nicknamed Hecate, showed a therapeutic window estimated at...
A single corporate decision erased a patent for a compound that promised antidepressant effects without hallucinations. DOET, nicknamed Hecate, showed a therapeutic window estimated at five-fold or greater and produced no open-eye hallucinations in controlled tests - so why was it abandoned before it could become medicine?

In this episode, we trace the timeline from a 1966 patent filing through company withdrawal and a 1968 Johns Hopkins trial, asking how external social panic over a related street drug redirected scientific progress. What happened between bench notes and boardroom memos that ended DOET’s chances?

Person: Alexander Shulgin
Organization: Dow Chemical
Person: Solomon Snyder
Date: 1966
Date: 1968

- DOET (Hecate) patent filed by Dow Chemical in 1966.
- Shulgin estimated DOET’s therapeutic window at five-fold or greater compared to LSD and DOM’s two-to-three-fold.
- Johns Hopkins trial published in 1968 used 1.5 mg DOET hydrochloride orally.
- Reported onset in trial: 1 to 1.5 hours; peak duration: 3 to 4 hours; total resolution: 5 to 6 hours.
- Dow terminated the DOET program in 1968 after public crises linked to high-dose DOM (STP) in San Francisco.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1243falsefullhttps://www.spreaker.com/episode/when-a-single-carbon-killed-a-drug-the-doet-molecule-s-lost-promise--73098182
A single-carbon change turned DOM into DOET - a molecule that produced clear-headed euphoria in one test and deep lethargy in another - yet it never reached patients because a separate street crisis exploded. How did a San Francisco outbreak tied to an entirely different compound bury a promising pharmaceutical before science could finish it?

In this episode, we trace the path from a Dow Chemical lab to a Schedule I classification, following patent filings, a contested disclosure to a clandestine manufacturer, and a halted clinical program. What was lost to medicine when DOET vanished under the weight of a public health scandal?

Person: Alexander Shulgin
Person: Owsley Stanley
Institution: Dow Chemical
Date: 1966
Dose: 1.5 milligrams

- Shulgin synthesized DOM in 1963 and discovered its psychedelic properties in 1964.
- Shulgin modified DOM at the four-position (methyl to ethyl) to create DOET in 1964-1965.
- Shulgin filed a patent for DOET with Dow Chemical in 1966.
- Owsley Stanley synthesized high-dose DOM tablets distributed in San Francisco in 1967 under the name STP, causing hospitalizations and a public health crisis.
- Johns Hopkins neuroscientist Solomon H. Snyder administered 1.5 mg of DOET in the first controlled human trial and reported mild euphoria.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098182Wed, 22 Jul 2026 02:53:55 +0000Creator at ObomediaWhen a Single Carbon Killed a Drug: The DOET Molecule's Lost Promise A single-carbon change turned DOM into DOET - a molecule that produced clear-headed euphoria in one test and deep lethargy in another - yet it never reached patients because a...
A single-carbon change turned DOM into DOET - a molecule that produced clear-headed euphoria in one test and deep lethargy in another - yet it never reached patients because a separate street crisis exploded. How did a San Francisco outbreak tied to an entirely different compound bury a promising pharmaceutical before science could finish it?

In this episode, we trace the path from a Dow Chemical lab to a Schedule I classification, following patent filings, a contested disclosure to a clandestine manufacturer, and a halted clinical program. What was lost to medicine when DOET vanished under the weight of a public health scandal?

Person: Alexander Shulgin
Person: Owsley Stanley
Institution: Dow Chemical
Date: 1966
Dose: 1.5 milligrams

- Shulgin synthesized DOM in 1963 and discovered its psychedelic properties in 1964.
- Shulgin modified DOM at the four-position (methyl to ethyl) to create DOET in 1964-1965.
- Shulgin filed a patent for DOET with Dow Chemical in 1966.
- Owsley Stanley synthesized high-dose DOM tablets distributed in San Francisco in 1967 under the name STP, causing hospitalizations and a public health crisis.
- Johns Hopkins neuroscientist Solomon H. Snyder administered 1.5 mg of DOET in the first controlled human trial and reported mild euphoria.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1150falsefullhttps://www.spreaker.com/episode/the-drug-that-shouldn-t-exist-how-ariadne-vanished-after-300mg--73098178
A single extra carbon atom turned a known psychedelic into a molecule that, at 300 mg, produced clarity instead of hallucinations - and then disappeared from public view. What happened when Ariadne did something science said was impossible, and why was all trial data withheld?

In this episode, we tell the story of the molecule Ariadne and the scientist who created it, following the compound from synthesis through Phase Three trials and into the unexplained gap in the public record. How did a change of one carbon yield therapeutic effects without hallucination, and why did development stop?

Person: Alexander Shulgin
Date: 1968
Compound: Ariadne
Dose reported: 300 mg
Company involved: Bristol Laboratories

- Shulgin synthesized Ariadne in 1968 by replacing a methyl group with an ethyl group on DOM.
- DOM produces full psychedelia above 3 mg, while Ariadne at 300 mg produced no hallucinations.
- At 25-50 mg Ariadne caused increased mental alertness and well-being in subjects.
- At 50-100 mg researchers noted improvements in manic depression and psychotic presentations.
- At 100 mg per day Ariadne appeared to address symptoms of Parkinson’s disease.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098178Wed, 22 Jul 2026 02:53:43 +0000Creator at ObomediaThe Drug That Shouldn't Exist: How Ariadne Vanished After 300mg A single extra carbon atom turned a known psychedelic into a molecule that, at 300 mg, produced clarity instead of hallucinations - and then disappeared from public view. What happened...
A single extra carbon atom turned a known psychedelic into a molecule that, at 300 mg, produced clarity instead of hallucinations - and then disappeared from public view. What happened when Ariadne did something science said was impossible, and why was all trial data withheld?

In this episode, we tell the story of the molecule Ariadne and the scientist who created it, following the compound from synthesis through Phase Three trials and into the unexplained gap in the public record. How did a change of one carbon yield therapeutic effects without hallucination, and why did development stop?

Person: Alexander Shulgin
Date: 1968
Compound: Ariadne
Dose reported: 300 mg
Company involved: Bristol Laboratories

- Shulgin synthesized Ariadne in 1968 by replacing a methyl group with an ethyl group on DOM.
- DOM produces full psychedelia above 3 mg, while Ariadne at 300 mg produced no hallucinations.
- At 25-50 mg Ariadne caused increased mental alertness and well-being in subjects.
- At 50-100 mg researchers noted improvements in manic depression and psychotic presentations.
- At 100 mg per day Ariadne appeared to address symptoms of Parkinson’s disease.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1177falsefullhttps://www.spreaker.com/episode/the-girl-who-broke-hormones-how-an-epilepsy-drug-became-cancer-s-key--73098174
Aminoglutethimide silenced seizures - and within weeks it nearly silenced a young girl's adrenal glands, producing a clinical picture indistinguishable from Addison's disease. What began as an anticonvulsant trial turned into the first hint that a brain drug could dismantle the body's hormonal architecture; how did a molecule meant for neurons stop hormone production at its source?

In this episode, we tell how clinicians in 1963 documented a patient whose adrenal function collapsed after taking aminoglutethimide, and how that observation redirected thinking about the drug's effects on endocrine systems. Follow the clinical notes and chemical history that turned an epilepsy medication into a clue about steroid synthesis - and ask what mechanism could link a glutarimide to adrenal suppression?

Person: unnamed young female patient
Date: 1963
Drug: aminoglutethimide (Ba 16038, Ciba 16038; brand name Elipten)
Adverse effect frequency: 45-85% experienced at least one adverse effect
Specific severe effect frequency: ~10% experienced circulatory collapse/adrenal insufficiency

- Aminoglutethimide was introduced in 1960 and marketed as the anticonvulsant Elipten for petit mal epilepsy.
- Lethargy occurred in 31-70% of patients depending on dose.
- Approximately 10% of patients developed circulatory collapse with signs of adrenal insufficiency.
- Clinicians in 1963 recorded a patient with near-complete suppression of adrenal hormone production resembling Addison's disease.
- The compound belonged to the nonsteroidal glutarimide family and was chemically related to glutethimide and, more distantly, thalidomide.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098174Wed, 22 Jul 2026 02:53:31 +0000Creator at ObomediaThe Girl Who Broke Hormones: How an Epilepsy Drug Became Cancer's Key Aminoglutethimide silenced seizures - and within weeks it nearly silenced a young girl's adrenal glands, producing a clinical picture indistinguishable from Addison's disease....
Aminoglutethimide silenced seizures - and within weeks it nearly silenced a young girl's adrenal glands, producing a clinical picture indistinguishable from Addison's disease. What began as an anticonvulsant trial turned into the first hint that a brain drug could dismantle the body's hormonal architecture; how did a molecule meant for neurons stop hormone production at its source?

In this episode, we tell how clinicians in 1963 documented a patient whose adrenal function collapsed after taking aminoglutethimide, and how that observation redirected thinking about the drug's effects on endocrine systems. Follow the clinical notes and chemical history that turned an epilepsy medication into a clue about steroid synthesis - and ask what mechanism could link a glutarimide to adrenal suppression?

Person: unnamed young female patient
Date: 1963
Drug: aminoglutethimide (Ba 16038, Ciba 16038; brand name Elipten)
Adverse effect frequency: 45-85% experienced at least one adverse effect
Specific severe effect frequency: ~10% experienced circulatory collapse/adrenal insufficiency

- Aminoglutethimide was introduced in 1960 and marketed as the anticonvulsant Elipten for petit mal epilepsy.
- Lethargy occurred in 31-70% of patients depending on dose.
- Approximately 10% of patients developed circulatory collapse with signs of adrenal insufficiency.
- Clinicians in 1963 recorded a patient with near-complete suppression of adrenal hormone production resembling Addison's disease.
- The compound belonged to the nonsteroidal glutarimide family and was chemically related to glutethimide and, more distantly, thalidomide.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1223falsefullhttps://www.spreaker.com/episode/the-number-is-fifteen-human-stakes-households-discarding-meds-foreign-hospitals-denied-donations--73098171
Imagine learning a federal study found roughly nine out of ten drugs remain safe and effective up to fifteen years past their printed date - yet that finding has been hidden from the public for four decades. How did a program that could change what we throw away become locked behind a government nondisclosure?

In this episode, we walk through the origin, findings, and secrecy of the Shelf Life Extension Program and why its results about expired medications were never released, leaving households and humanitarian actors in the dark. What happens when government science about drugs becomes classified, and who pays the price?

Person: Joel Davis
Program: Shelf Life Extension Program (SLEP)
Agencies: U.S. Department of Defense and Food and Drug Administration
Study size: more than 100 drugs tested
Key finding: roughly 90% effective up to 15 years past label under controlled storage

- A federal study tested over 100 drugs and found about 9 out of 10 remained effective up to 15 years after their printed expiration.
- The program began in the mid-1980s after DoD faced unsustainable costs discarding medications from global stockpiles.
- Cipro was shown effective 9 years past its labeled shelf life in controlled testing on stockpiled samples.
- The memorandum founding SLEP formally barred disclosure of the data to the public, other agencies, manufacturers, or foreign governments.
- Temperature was identified as the dominant variable in degradation, with chemical reaction rates roughly doubling for every 10°C increase.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098171Wed, 22 Jul 2026 02:53:19 +0000Creator at ObomediaThe number is fifteen. Human stakes: households discarding meds; foreign hospitals denied donations Imagine learning a federal study found roughly nine out of ten drugs remain safe and effective up to fifteen years past their printed date - yet...
Imagine learning a federal study found roughly nine out of ten drugs remain safe and effective up to fifteen years past their printed date - yet that finding has been hidden from the public for four decades. How did a program that could change what we throw away become locked behind a government nondisclosure?

In this episode, we walk through the origin, findings, and secrecy of the Shelf Life Extension Program and why its results about expired medications were never released, leaving households and humanitarian actors in the dark. What happens when government science about drugs becomes classified, and who pays the price?

Person: Joel Davis
Program: Shelf Life Extension Program (SLEP)
Agencies: U.S. Department of Defense and Food and Drug Administration
Study size: more than 100 drugs tested
Key finding: roughly 90% effective up to 15 years past label under controlled storage

- A federal study tested over 100 drugs and found about 9 out of 10 remained effective up to 15 years after their printed expiration.
- The program began in the mid-1980s after DoD faced unsustainable costs discarding medications from global stockpiles.
- Cipro was shown effective 9 years past its labeled shelf life in controlled testing on stockpiled samples.
- The memorandum founding SLEP formally barred disclosure of the data to the public, other agencies, manufacturers, or foreign governments.
- Temperature was identified as the dominant variable in degradation, with chemical reaction rates roughly doubling for every 10°C increase.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1181falsefullhttps://www.spreaker.com/episode/the-iron-lung-that-made-a-drug-safety-rebel-and-a-missing-memo--73098168
A Cambridge medical student spent nearly two years sealed inside an iron lung in the early 1950s, later delivering fifty babies from an adapted wheelchair and building a national drug safety system after thalidomide crippled thousands; yet a corporate memo decades later claimed he had destroyed his own review records-what really happened to those files?

In this episode, we trace his life from Banstead to Cambridge and through a career that moved from hospital wards to the heart of Britain’s drug-safety apparatus, asking how a man who survived paralysis became an agitator for systems that could prevent another catastrophe and what the missing memo implies about his legacy.

Person: William Howard Wallace Inman
Date of birth: 1 August 1929
Condition: Polio with two years in an iron lung in the early 1950s
Event: Thalidomide disaster with more than 10,000 children affected worldwide and approximately 2,000 in Britain
Initiative: Yellow Card reporting system commissioned by Sir Derrick Dunlop for the Committee on Safety of Medicines

- He spent approximately two years in an iron lung, a negative-pressure ventilator that enclosed the body from the neck down.
- He became the first clinical medical graduate of Cambridge University to complete training while affected by his condition, finishing in 1956.
- He delivered fifty babies from an adapted wheelchair while working at Addenbrooke’s Hospital.
- He worked as a medical adviser at ICI’s Pharmaceutical Division from 1959 to 1964.
- The thalidomide disaster caused limb malformations in more than 10,000 children worldwide and about 2,000 in Britain, prompting the Yellow Card system in 1964.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098168Wed, 22 Jul 2026 02:53:07 +0000Creator at ObomediaThe Iron Lung That Made a Drug-Safety Rebel-and a Missing Memo A Cambridge medical student spent nearly two years sealed inside an iron lung in the early 1950s, later delivering fifty babies from an adapted wheelchair and building a national drug...
A Cambridge medical student spent nearly two years sealed inside an iron lung in the early 1950s, later delivering fifty babies from an adapted wheelchair and building a national drug safety system after thalidomide crippled thousands; yet a corporate memo decades later claimed he had destroyed his own review records-what really happened to those files?

In this episode, we trace his life from Banstead to Cambridge and through a career that moved from hospital wards to the heart of Britain’s drug-safety apparatus, asking how a man who survived paralysis became an agitator for systems that could prevent another catastrophe and what the missing memo implies about his legacy.

Person: William Howard Wallace Inman
Date of birth: 1 August 1929
Condition: Polio with two years in an iron lung in the early 1950s
Event: Thalidomide disaster with more than 10,000 children affected worldwide and approximately 2,000 in Britain
Initiative: Yellow Card reporting system commissioned by Sir Derrick Dunlop for the Committee on Safety of Medicines

- He spent approximately two years in an iron lung, a negative-pressure ventilator that enclosed the body from the neck down.
- He became the first clinical medical graduate of Cambridge University to complete training while affected by his condition, finishing in 1956.
- He delivered fifty babies from an adapted wheelchair while working at Addenbrooke’s Hospital.
- He worked as a medical adviser at ICI’s Pharmaceutical Division from 1959 to 1964.
- The thalidomide disaster caused limb malformations in more than 10,000 children worldwide and about 2,000 in Britain, prompting the Yellow Card system in 1964.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1161falsefullhttps://www.spreaker.com/episode/a-small-bottle-labeled-soothing-condemned-as-baby-killers--73098166
A small apron-pocket bottle sold for teething promised relief but was publicly branded "Baby Killers" by the American Medical Association in 1911 - yet it stayed on UK shelves until 1930. How could a product condemned by doctors remain legally available and reshape generations before regulators caught up?

In this episode, we trace the circulation of Mrs. Winslow's Soothing Syrup, its marketing and everyday use, the 1911 AMA condemnation, and the regulatory gaps that allowed legal sale in the United Kingdom until 1930. What does the syrup's longevity reveal about the limits of professional censure and the mechanics of recalls?

Person: Mrs. Winslow's Soothing Syrup
Date: 1911 AMA article condemning the product
Location: United Kingdom (legal availability until 1930)
Event: Continued legal sale despite AMA condemnation
Topic: Misbranding as largest cause of modern drug recalls

- The American Medical Association published an article titled "Baby Killers" about the syrup in 1911.
- Mrs. Winslow's Soothing Syrup remained legally available in the United Kingdom until 1930.
- In 2015, misbranding accounted for 42% of all drug recall cases in the United Kingdom.
- The FDA assigns recall classes I, II, and III based on the severity of harm and evidence from a Health Hazard Assessment.
- Over-the-counter products often lack a direct manufacturer-to-patient link, complicating targeted recalls that rely on lot numbers.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098166Wed, 22 Jul 2026 02:52:54 +0000Creator at Obomediaa small bottle labeled soothing, condemned as Baby Killers A small apron-pocket bottle sold for teething promised relief but was publicly branded "Baby Killers" by the American Medical Association in 1911 - yet it stayed on UK shelves until 1930....
A small apron-pocket bottle sold for teething promised relief but was publicly branded "Baby Killers" by the American Medical Association in 1911 - yet it stayed on UK shelves until 1930. How could a product condemned by doctors remain legally available and reshape generations before regulators caught up?

In this episode, we trace the circulation of Mrs. Winslow's Soothing Syrup, its marketing and everyday use, the 1911 AMA condemnation, and the regulatory gaps that allowed legal sale in the United Kingdom until 1930. What does the syrup's longevity reveal about the limits of professional censure and the mechanics of recalls?

Person: Mrs. Winslow's Soothing Syrup
Date: 1911 AMA article condemning the product
Location: United Kingdom (legal availability until 1930)
Event: Continued legal sale despite AMA condemnation
Topic: Misbranding as largest cause of modern drug recalls

- The American Medical Association published an article titled "Baby Killers" about the syrup in 1911.
- Mrs. Winslow's Soothing Syrup remained legally available in the United Kingdom until 1930.
- In 2015, misbranding accounted for 42% of all drug recall cases in the United Kingdom.
- The FDA assigns recall classes I, II, and III based on the severity of harm and evidence from a Health Hazard Assessment.
- Over-the-counter products often lack a direct manufacturer-to-patient link, complicating targeted recalls that rely on lot numbers.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1114falsefullhttps://www.spreaker.com/episode/a-paralyzed-dropout-became-a-billionaire-then-the-government-destroyed-everything-he-built--73098164
Fear and astonishment: a man doctors declared permanently paralyzed at 17 walked out of that prognosis, later chartered twenty-seven Boeing 747s to fly his entire company to Disney, and then watched a federal indictment obliterate a business that had helped 4.5 million people; how did a staircase and a jury verdict lead to those jets? What happened between the conviction that never came and the jobs that never returned?

In this episode, we tell the life and rise of Bill Bartmann and the corporate saga that followed, from a carnival dropout in Dubuque to a debt-relief company that altered how charge-off loans were handled - and the federal case that destroyed his company even after he was acquitted. How did his method of buying and restructuring defaulted loans scale into a business that employed thousands and then vanish after indictment?

Person: Bill Bartmann
Location: Dubuque, Iowa and Muskogee, Oklahoma
Event: Purchase and restructuring of defaulted federal loan portfolio
Case: Federal indictment followed by jury acquittal on every charge
Impact: 3,900 jobs lost and 4.5 million people helped prior to shutdown

- At 14, Bartmann dropped out of school in approximately 1962 to join a travelling carnival.
- At 17 he fell down a staircase, was told his paralysis was permanent, and later regained use of his legs through nightly physical regimen.
- By buying a portfolio of defaulted federal loans he repaid a $1,000,000 personal liability and founded a debt-restructuring business model.
- His company chartered twenty-seven Boeing 747s to fly every employee to Walt Disney World for a corporate celebration.
- After a federal indictment the company folded: 3,900 jobs did not return despite Bartmann’s later acquittal on all charges.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098164Wed, 22 Jul 2026 02:52:42 +0000Creator at ObomediaA paralyzed dropout became a billionaire - then the government destroyed everything he built Fear and astonishment: a man doctors declared permanently paralyzed at 17 walked out of that prognosis, later chartered twenty-seven Boeing 747s to fly his...
Fear and astonishment: a man doctors declared permanently paralyzed at 17 walked out of that prognosis, later chartered twenty-seven Boeing 747s to fly his entire company to Disney, and then watched a federal indictment obliterate a business that had helped 4.5 million people; how did a staircase and a jury verdict lead to those jets? What happened between the conviction that never came and the jobs that never returned?

In this episode, we tell the life and rise of Bill Bartmann and the corporate saga that followed, from a carnival dropout in Dubuque to a debt-relief company that altered how charge-off loans were handled - and the federal case that destroyed his company even after he was acquitted. How did his method of buying and restructuring defaulted loans scale into a business that employed thousands and then vanish after indictment?

Person: Bill Bartmann
Location: Dubuque, Iowa and Muskogee, Oklahoma
Event: Purchase and restructuring of defaulted federal loan portfolio
Case: Federal indictment followed by jury acquittal on every charge
Impact: 3,900 jobs lost and 4.5 million people helped prior to shutdown

- At 14, Bartmann dropped out of school in approximately 1962 to join a travelling carnival.
- At 17 he fell down a staircase, was told his paralysis was permanent, and later regained use of his legs through nightly physical regimen.
- By buying a portfolio of defaulted federal loans he repaid a $1,000,000 personal liability and founded a debt-restructuring business model.
- His company chartered twenty-seven Boeing 747s to fly every employee to Walt Disney World for a corporate celebration.
- After a federal indictment the company folded: 3,900 jobs did not return despite Bartmann’s later acquittal on all charges.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1058falsefullhttps://www.spreaker.com/episode/the-teacher-the-flood-and-the-four-men-who-stole-a-nation-s-bank--73098162
A tiny nation of roughly ten thousand people lost three villages to the Alpine Rhine on September 25, 1927, while at the same time a coordinated theft drained four million Swiss francs from its bank. Who were the four men who emptied the treasury, and why did the scandal end Gustav Schädler's career within a single week in June 1928?

In this episode, we tell how a schoolteacher turned prime minister managed floods, emergency loans, and the creation of Liechtenstein's first power plant, even as insiders looted the national bank; could the same political reshaping that stabilized the country also have enabled its undoing?

Person: Gustav Schädler
Date: September 25, 1927
Event: Alpine Rhine flood swallowed three villages
Amount: 4,000,000 Swiss francs stolen
Persons: Franz Thöny, Anton Walser, Niko Beck, Rudolf Carbone

- Liechtenstein's population was roughly ten thousand people in the 1920s.
- The flood occurred on the morning of September 25, 1927, and resulted in two deaths.
- Prince Johann II donated one million Swiss francs from his personal fortune after the flood.
- Gustav Schädler became Prime Minister on June 6, 1922, at age thirty-eight.
- Four million Swiss francs were drained through speculative transactions between 1926 and 1928.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098162Wed, 22 Jul 2026 02:52:30 +0000Creator at ObomediaThe Teacher, The Flood, and the Four Men Who Stole a Nation's Bank A tiny nation of roughly ten thousand people lost three villages to the Alpine Rhine on September 25, 1927, while at the same time a coordinated theft drained four million Swiss...
A tiny nation of roughly ten thousand people lost three villages to the Alpine Rhine on September 25, 1927, while at the same time a coordinated theft drained four million Swiss francs from its bank. Who were the four men who emptied the treasury, and why did the scandal end Gustav Schädler's career within a single week in June 1928?

In this episode, we tell how a schoolteacher turned prime minister managed floods, emergency loans, and the creation of Liechtenstein's first power plant, even as insiders looted the national bank; could the same political reshaping that stabilized the country also have enabled its undoing?

Person: Gustav Schädler
Date: September 25, 1927
Event: Alpine Rhine flood swallowed three villages
Amount: 4,000,000 Swiss francs stolen
Persons: Franz Thöny, Anton Walser, Niko Beck, Rudolf Carbone

- Liechtenstein's population was roughly ten thousand people in the 1920s.
- The flood occurred on the morning of September 25, 1927, and resulted in two deaths.
- Prince Johann II donated one million Swiss francs from his personal fortune after the flood.
- Gustav Schädler became Prime Minister on June 6, 1922, at age thirty-eight.
- Four million Swiss francs were drained through speculative transactions between 1926 and 1928.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1025falsefullhttps://www.spreaker.com/episode/the-president-who-died-abroad-zambia-s-unsettled-funeral-war--73098158
Grief turned into courtroom conflict the morning Edgar Chagwa Lungu died on June 5, 2025, at Mediclinic Medforum in Pretoria, and Zambia declared seven days of mourning for a body it could not yet bring home. How did a surgical death trigger a months-long legal and political battle that still hasn't settled where his coffin should rest?

In this episode, we trace the arc of Lungu’s life from Ndola Central Hospital in 1956 through a career as lawyer, soldier, and president, and then into the contested hours after his death - a family banning a sitting head of state from the coffin, a court order halting a funeral, and the national fallout that followed. What does this unsettled funeral war reveal about Zambia’s politics and institutions?

Person: Edgar Chagwa Lungu
Date of death: June 5, 2025
Location of death: Mediclinic Medforum, Pretoria, South Africa
Age: 68
Period as president: sworn in January 26, 2015

- Lungu was born on November 11, 1956, at Ndola Central Hospital in the Copperbelt.
- He married Esther in 1986 and they had six children, including Tasila Lungu.
- Tasila Lungu won the parliamentary seat for Chawama constituency in 2021.
- Lungu finished seventh with 2.43% of the vote in Chawama in 2001.
- He won the 2015 presidential by-election by 27,757 votes with a turnout of 32.36% and a margin of 1.66%.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098158Wed, 22 Jul 2026 02:52:18 +0000Creator at ObomediaThe President Who Died Abroad - Zambia's Unsettled Funeral War Grief turned into courtroom conflict the morning Edgar Chagwa Lungu died on June 5, 2025, at Mediclinic Medforum in Pretoria, and Zambia declared seven days of mourning for a body it...
Grief turned into courtroom conflict the morning Edgar Chagwa Lungu died on June 5, 2025, at Mediclinic Medforum in Pretoria, and Zambia declared seven days of mourning for a body it could not yet bring home. How did a surgical death trigger a months-long legal and political battle that still hasn't settled where his coffin should rest?

In this episode, we trace the arc of Lungu’s life from Ndola Central Hospital in 1956 through a career as lawyer, soldier, and president, and then into the contested hours after his death - a family banning a sitting head of state from the coffin, a court order halting a funeral, and the national fallout that followed. What does this unsettled funeral war reveal about Zambia’s politics and institutions?

Person: Edgar Chagwa Lungu
Date of death: June 5, 2025
Location of death: Mediclinic Medforum, Pretoria, South Africa
Age: 68
Period as president: sworn in January 26, 2015

- Lungu was born on November 11, 1956, at Ndola Central Hospital in the Copperbelt.
- He married Esther in 1986 and they had six children, including Tasila Lungu.
- Tasila Lungu won the parliamentary seat for Chawama constituency in 2021.
- Lungu finished seventh with 2.43% of the vote in Chawama in 2001.
- He won the 2015 presidential by-election by 27,757 votes with a turnout of 32.36% and a margin of 1.66%.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1106falsefullhttps://www.spreaker.com/episode/when-safety-explodes-the-takata-airbag-that-killed-a-pregnant-woman--73098155
A pregnant driver and her newborn died after a Takata airbag sent a metal fragment through her neck when the car impacted at 30 kilometers per hour; the inflator ruptured in an 11-year-old Honda City exposed to Malaysian heat and humidity. How did a safety company’s decades-long choice to use ammonium nitrate - a cheaper, moisture-sensitive propellant - turn into a predictable chain of fatal ruptures across more than 100 million vehicles?

In this episode, we trace Takata’s origins as a parachute fabric maker through its rise to holding roughly 20 percent of the global airbag market, the decision in the late 1990s to adopt ammonium nitrate, and the sequence of recalls, injuries, and deaths that followed - asking how many documented warnings it took before action was effective.

Person: Unnamed 42-year-old woman (driver)
Event: Airbag inflator rupture that sent metal fragment into neck
Date: July 2014 (fatal crash in Malaysia); recalls noted June 2014
Location: Malaysia; vehicle was a 2003 Honda City, 11 years old
Topic: Takata airbag defect using ammonium nitrate propellant

- Airbag deployed at 30 kilometers per hour in a minor collision while the car remained drivable.
- The driver was 42 years old and eight months pregnant; she died before reaching the hospital.
- The infant was delivered after the mother’s death and lived three days.
- Takata held roughly 20 percent of the worldwide airbag market by 2014, installed in over 100 million vehicles across more than 20 carmakers.
- By September 2024, investigators attributed 35 worldwide deaths to Takata airbags, with 28 in the United States and recalls still being issued.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098155Wed, 22 Jul 2026 02:52:07 +0000Creator at ObomediaWhen Safety Explodes: The Takata Airbag That Killed a Pregnant Woman A pregnant driver and her newborn died after a Takata airbag sent a metal fragment through her neck when the car impacted at 30 kilometers per hour; the inflator ruptured in an...
A pregnant driver and her newborn died after a Takata airbag sent a metal fragment through her neck when the car impacted at 30 kilometers per hour; the inflator ruptured in an 11-year-old Honda City exposed to Malaysian heat and humidity. How did a safety company’s decades-long choice to use ammonium nitrate - a cheaper, moisture-sensitive propellant - turn into a predictable chain of fatal ruptures across more than 100 million vehicles?

In this episode, we trace Takata’s origins as a parachute fabric maker through its rise to holding roughly 20 percent of the global airbag market, the decision in the late 1990s to adopt ammonium nitrate, and the sequence of recalls, injuries, and deaths that followed - asking how many documented warnings it took before action was effective.

Person: Unnamed 42-year-old woman (driver)
Event: Airbag inflator rupture that sent metal fragment into neck
Date: July 2014 (fatal crash in Malaysia); recalls noted June 2014
Location: Malaysia; vehicle was a 2003 Honda City, 11 years old
Topic: Takata airbag defect using ammonium nitrate propellant

- Airbag deployed at 30 kilometers per hour in a minor collision while the car remained drivable.
- The driver was 42 years old and eight months pregnant; she died before reaching the hospital.
- The infant was delivered after the mother’s death and lived three days.
- Takata held roughly 20 percent of the worldwide airbag market by 2014, installed in over 100 million vehicles across more than 20 carmakers.
- By September 2024, investigators attributed 35 worldwide deaths to Takata airbags, with 28 in the United States and recalls still being issued.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1245falsefullhttps://www.spreaker.com/episode/when-the-sea-poisoned-a-town-the-slow-horror-of-minamata--73098151
The sea that fed Minamata became a silent killer: by the mid-1950s fish catches in Minamata Bay had fallen by 91% while a factory discharged methylmercury that bioaccumulated in seafood. How did a company that provided over 25% of local jobs and more than half the city's tax revenue become the epicenter of one of the worst industrial poisoning disasters in recorded history?

In this episode, we tell the sequence of events from the opening of Chisso's plant in 1908 through the spike in acetaldehyde production and the 1951 catalyst change that created methylmercury, asking how economic dependency and slow environmental change allowed thousands to be poisoned before the truth emerged.

Person: Chisso Corporation factory director (reported epidemic)
Location: Minamata, Kyūshū, Japan
Date: May 1, 1956 (epidemic reported)
Period: 1932-1956 (acetaldehyde production growth)
Event: Kumamoto University Research Group formed August 1956

- Chisso provided more than 25% of local jobs and more than half the city's tax revenue.
- Acetaldehyde output rose from 210 tons in 1932 to 6,000 tons by 1951.
- In August 1951 Chisso changed its catalyst to ferric sulfide, producing roughly 5% of outflow as methylmercury.
- Between 1953 and 1957 fish catches in Minamata Bay fell by 91%.
- By October 1956 the Kumamoto University Research Group had documented 40 patients, 14 of whom were dead (a 35% case fatality rate).

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098151Wed, 22 Jul 2026 02:51:54 +0000Creator at ObomediaWhen the Sea Poisoned a Town: The Slow Horror of Minamata The sea that fed Minamata became a silent killer: by the mid-1950s fish catches in Minamata Bay had fallen by 91% while a factory discharged methylmercury that bioaccumulated in seafood. How...
The sea that fed Minamata became a silent killer: by the mid-1950s fish catches in Minamata Bay had fallen by 91% while a factory discharged methylmercury that bioaccumulated in seafood. How did a company that provided over 25% of local jobs and more than half the city's tax revenue become the epicenter of one of the worst industrial poisoning disasters in recorded history?

In this episode, we tell the sequence of events from the opening of Chisso's plant in 1908 through the spike in acetaldehyde production and the 1951 catalyst change that created methylmercury, asking how economic dependency and slow environmental change allowed thousands to be poisoned before the truth emerged.

Person: Chisso Corporation factory director (reported epidemic)
Location: Minamata, Kyūshū, Japan
Date: May 1, 1956 (epidemic reported)
Period: 1932-1956 (acetaldehyde production growth)
Event: Kumamoto University Research Group formed August 1956

- Chisso provided more than 25% of local jobs and more than half the city's tax revenue.
- Acetaldehyde output rose from 210 tons in 1932 to 6,000 tons by 1951.
- In August 1951 Chisso changed its catalyst to ferric sulfide, producing roughly 5% of outflow as methylmercury.
- Between 1953 and 1957 fish catches in Minamata Bay fell by 91%.
- By October 1956 the Kumamoto University Research Group had documented 40 patients, 14 of whom were dead (a 35% case fatality rate).

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1142falsefullhttps://www.spreaker.com/episode/shallow-crater-massive-deaths-unpacking-the-al-ahli-hospital-blast--73098149
The tiniest crater - roughly one meter long and 30-40 cm deep - became the center of a global outrage that claimed between 200 and 500 lives in hours. Why did a shallow, table-sized hole at al-Ahli Arab Hospital produce such a vast and disputed casualty count, and what does the physical evidence actually say?

In this episode, we lay out the documented timeline, the physical measurements, and the recorded warnings that framed the evening of October 17, 2023, presenting what is known and what remains unresolved: how did hundreds die beside a crater smaller than a bathtub?

Person: Reverend Hosam Naoum
Location: al-Ahli Arab Hospital compound, Gaza City
Date: October 17, 2023, 18:59 local time
Event: Courtyard explosion in hospital driveway
Period: Days after Israeli evacuation orders issued for northern Gaza

- Al Jazeera captured five explosions over Gaza City that evening, the fifth landing in the hospital courtyard.
- Approximately 1,000 displaced Palestinians were sheltering on the hospital grounds at the time.
- The crater measured roughly 1 meter long and 30-40 centimeters deep according to multiple investigations.
- Reported immediate death tolls ranged from 200 to 500 people within hours after the blast.
- On October 14, a 155-mm artillery illumination shell struck the hospital’s cancer center, injuring four staff and damaging upper floors.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098149Wed, 22 Jul 2026 02:51:43 +0000Creator at ObomediaShallow Crater, Massive Deaths: Unpacking the Al-Ahli Hospital Blast The tiniest crater - roughly one meter long and 30-40 cm deep - became the center of a global outrage that claimed between 200 and 500 lives in hours. Why did a shallow,...
The tiniest crater - roughly one meter long and 30-40 cm deep - became the center of a global outrage that claimed between 200 and 500 lives in hours. Why did a shallow, table-sized hole at al-Ahli Arab Hospital produce such a vast and disputed casualty count, and what does the physical evidence actually say?

In this episode, we lay out the documented timeline, the physical measurements, and the recorded warnings that framed the evening of October 17, 2023, presenting what is known and what remains unresolved: how did hundreds die beside a crater smaller than a bathtub?

Person: Reverend Hosam Naoum
Location: al-Ahli Arab Hospital compound, Gaza City
Date: October 17, 2023, 18:59 local time
Event: Courtyard explosion in hospital driveway
Period: Days after Israeli evacuation orders issued for northern Gaza

- Al Jazeera captured five explosions over Gaza City that evening, the fifth landing in the hospital courtyard.
- Approximately 1,000 displaced Palestinians were sheltering on the hospital grounds at the time.
- The crater measured roughly 1 meter long and 30-40 centimeters deep according to multiple investigations.
- Reported immediate death tolls ranged from 200 to 500 people within hours after the blast.
- On October 14, a 155-mm artillery illumination shell struck the hospital’s cancer center, injuring four staff and damaging upper floors.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1166falsefullhttps://www.spreaker.com/episode/the-gravy-crystals-how-melamine-turned-pet-food-deadly--73098146
Visible industrial crystals settled in the gravy of canned pet food, and more than five thousand products were pulled from shelves across the United States and Canada. How did an industrial chemical like melamine end up visible in wheat gluten and kill companion animals before anyone connected the dots?

In this episode, we trace the timeline from the first owner complaints to the March 16, 2007 voluntary recall, describe how a contract manufacturer allowed a single contaminated ingredient to spread across dozens of trusted brands, and ask how long pets had been exposed before anyone noticed.

Person: Stephen Sundlof
Company: Menu Foods
Date: March 16, 2007 (first voluntary recall announcement)
Event: Visible melamine crystals found in wheat gluten
Location: Streetsville, Ontario (Menu Foods operations)

- More than 5,000 pet food products were pulled from shelves across the United States and Canada.
- Menu Foods produced approximately 100 cat food brands and around 50 dog food brands under contract.
- First complaints to Menu Foods arrived on February 20, 2007; pets had been getting sick for at least 24 days by the March 16 announcement.
- Samples were sent to Cornell University's veterinary diagnostic laboratory March 13-15, 2007; the company announced the recall three days later on the evening of March 16.
- Stephen Sundlof and Cornell pathologists reported seeing melamine crystals visible to the naked eye in wheat gluten used in wet pet food.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098146Wed, 22 Jul 2026 02:51:30 +0000Creator at ObomediaThe Gravy Crystals: How Melamine Turned Pet Food Deadly Visible industrial crystals settled in the gravy of canned pet food, and more than five thousand products were pulled from shelves across the United States and Canada. How did an industrial...
Visible industrial crystals settled in the gravy of canned pet food, and more than five thousand products were pulled from shelves across the United States and Canada. How did an industrial chemical like melamine end up visible in wheat gluten and kill companion animals before anyone connected the dots?

In this episode, we trace the timeline from the first owner complaints to the March 16, 2007 voluntary recall, describe how a contract manufacturer allowed a single contaminated ingredient to spread across dozens of trusted brands, and ask how long pets had been exposed before anyone noticed.

Person: Stephen Sundlof
Company: Menu Foods
Date: March 16, 2007 (first voluntary recall announcement)
Event: Visible melamine crystals found in wheat gluten
Location: Streetsville, Ontario (Menu Foods operations)

- More than 5,000 pet food products were pulled from shelves across the United States and Canada.
- Menu Foods produced approximately 100 cat food brands and around 50 dog food brands under contract.
- First complaints to Menu Foods arrived on February 20, 2007; pets had been getting sick for at least 24 days by the March 16 announcement.
- Samples were sent to Cornell University's veterinary diagnostic laboratory March 13-15, 2007; the company announced the recall three days later on the evening of March 16.
- Stephen Sundlof and Cornell pathologists reported seeing melamine crystals visible to the naked eye in wheat gluten used in wet pet food.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>979falsefullhttps://www.spreaker.com/episode/when-the-vents-blew-how-armley-s-dust-killed-a-neighbourhood--73098143
A tiny industrial town became a slow-moving crime scene: blue asbestos from Midland Works settled on roughly 1,000 houses, coated windowsills, gutters and garden soil, and children played with the white dust that later killed them - so why did the vents keep blowing and the company keep quiet? What did the two people who never set foot inside the factory uncover about a neighbourhood sacrificed by profit and silence?

In this episode, we tell the story of the Midland Works on Canal Road in Armley and how its blue asbestos emissions affected ordinary residents across decades, following the legal battle brought by two locals and the internal company documents that revealed deliberate choices. How did known danger, buried waste, and corporate memos become the facts of a neighbourhood’s destruction?

Person: Arthur Margereson
Person: June Hancock
Location: Canal Road, Armley, Leeds
Period: early twentieth century to 1978
Company: Turner and Newall

- The factory processed crocidolite (blue asbestos) and employed around 250 people at its peak.
- Asbestos dust settled on about 1,000 houses in the Armley Lodge area.
- The factory developed Sprayed Limpet Asbestos by 1931 and exported it to 60 countries.
- Turner and Newall’s internal memo advised making only a “token effort” on safety to “ward off the evil day when asbestos cannot be economically applied.”
- In 1978 inspectors found a few hundred tonnes of blue asbestos waste mixed into the soil at Midland Works; Turner and Newall paid £15,000 toward the clean-up.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098143Wed, 22 Jul 2026 02:51:19 +0000Creator at ObomediaWhen the Vents Blew: How Armley's Dust Killed a Neighbourhood A tiny industrial town became a slow-moving crime scene: blue asbestos from Midland Works settled on roughly 1,000 houses, coated windowsills, gutters and garden soil, and children...
A tiny industrial town became a slow-moving crime scene: blue asbestos from Midland Works settled on roughly 1,000 houses, coated windowsills, gutters and garden soil, and children played with the white dust that later killed them - so why did the vents keep blowing and the company keep quiet? What did the two people who never set foot inside the factory uncover about a neighbourhood sacrificed by profit and silence?

In this episode, we tell the story of the Midland Works on Canal Road in Armley and how its blue asbestos emissions affected ordinary residents across decades, following the legal battle brought by two locals and the internal company documents that revealed deliberate choices. How did known danger, buried waste, and corporate memos become the facts of a neighbourhood’s destruction?

Person: Arthur Margereson
Person: June Hancock
Location: Canal Road, Armley, Leeds
Period: early twentieth century to 1978
Company: Turner and Newall

- The factory processed crocidolite (blue asbestos) and employed around 250 people at its peak.
- Asbestos dust settled on about 1,000 houses in the Armley Lodge area.
- The factory developed Sprayed Limpet Asbestos by 1931 and exported it to 60 countries.
- Turner and Newall’s internal memo advised making only a “token effort” on safety to “ward off the evil day when asbestos cannot be economically applied.”
- In 1978 inspectors found a few hundred tonnes of blue asbestos waste mixed into the soil at Midland Works; Turner and Newall paid £15,000 toward the clean-up.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1133falsefullhttps://www.spreaker.com/episode/the-surgeon-who-turned-care-into-killing-karl-brandt-s-secret-origins--73098141
A chilling conviction: Karl Brandt - once a gifted neurosurgeon and Hitler’s personal physician - died believing he was a healer even as he authorized the first state-sanctioned killing of a disabled infant that became a template for mass murder. How did medical training, academic theories of "merciful death," and intimate access to power transform a surgeon into an architect of systematic killing?

In this episode, we trace Brandt’s life from his January 8, 1904 birth in Mülhausen to his rise inside the Nazi elite, his early adoption of Nazi membership in 1932, and the July 25, 1939 decision to authorize the killing of five-month-old Gerhard Kretschmar - the act that served as the prototype for later programs. How did a physician’s clinic visit become the starting point for state euthanasia and medicalized mass murder?

Person: Karl Brandt
Date: January 8, 1904 (birth)
Location: Mülhausen
Event: Authorization of Gerhard Kretschmar’s killing on July 25, 1939
Rank: SS-Gruppenführer by April 1944

- Brandt completed his medical degree in 1928 and specialized in head and spinal injuries.
- He joined the Nazi Party in January 1932 at age 27.
- He married Anni Rehborn on March 17, 1934 and their son Karl Brandt was born October 4, 1935.
- Brandt attended courses by Alfred Hoche, a proponent of the concept of Gnadentod (merciful death).
- On July 25, 1939 Brandt examined five-month-old Gerhard Kretschmar and authorized his killing, then reported it had been carried out humanely.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098141Wed, 22 Jul 2026 02:51:06 +0000Creator at ObomediaThe Surgeon Who Turned Care into Killing: Karl Brandt's Secret Origins A chilling conviction: Karl Brandt - once a gifted neurosurgeon and Hitler’s personal physician - died believing he was a healer even as he authorized the first state-sanctioned...
A chilling conviction: Karl Brandt - once a gifted neurosurgeon and Hitler’s personal physician - died believing he was a healer even as he authorized the first state-sanctioned killing of a disabled infant that became a template for mass murder. How did medical training, academic theories of "merciful death," and intimate access to power transform a surgeon into an architect of systematic killing?

In this episode, we trace Brandt’s life from his January 8, 1904 birth in Mülhausen to his rise inside the Nazi elite, his early adoption of Nazi membership in 1932, and the July 25, 1939 decision to authorize the killing of five-month-old Gerhard Kretschmar - the act that served as the prototype for later programs. How did a physician’s clinic visit become the starting point for state euthanasia and medicalized mass murder?

Person: Karl Brandt
Date: January 8, 1904 (birth)
Location: Mülhausen
Event: Authorization of Gerhard Kretschmar’s killing on July 25, 1939
Rank: SS-Gruppenführer by April 1944

- Brandt completed his medical degree in 1928 and specialized in head and spinal injuries.
- He joined the Nazi Party in January 1932 at age 27.
- He married Anni Rehborn on March 17, 1934 and their son Karl Brandt was born October 4, 1935.
- Brandt attended courses by Alfred Hoche, a proponent of the concept of Gnadentod (merciful death).
- On July 25, 1939 Brandt examined five-month-old Gerhard Kretschmar and authorized his killing, then reported it had been carried out humanely.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1151falsefullhttps://www.spreaker.com/episode/when-the-nhs-knew-the-haemophilia-hiv-cover-up-that-killed-hundreds--73098138
Fear that the state betrayed the very patients it vowed to protect: over 100 plaintiffs were already dead while a senior judge begged the government to settle. How did pooled plasma, US paid donors, and delayed heat‑treatment turn routine haemophilia care into a mass public‑health catastrophe - and when did officials know the risk?

In this episode, we tell the story of the HIV haemophilia litigation and the institutional decisions behind it, following the record that links product sourcing, regulatory choices, and internal memos to the rising toll. Can the documents recovered from the Department of Archives show what officials knew and why the government refused to act sooner?

Person: plaintiffs numbering 1,217
Date: litigation commenced April 1989
Location: England and Wales
Event: internal Department of Archives memorandum (drafted 1995) reported publicly 4 February 2022
Status: 107 plaintiffs dead by the time any settlement was reached; 23 more died before the case closed

- 1,217 people filed suit in the HIV haemophilia group action.
- 107 of those 1,217 were already dead by the time any settlement was reached.
- 163 plaintiffs had progressed to full AIDS by November 1989, seven months after the case began.
- 600 historic Department of Archives files (covering 1972-1986) were central to the case and withheld by the Department.
- The defendants included 220 institutions, among them the Department of Archives and regional health authorities.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098138Wed, 22 Jul 2026 02:50:55 +0000Creator at ObomediaWhen the NHS Knew: The Haemophilia HIV Cover‑Up That Killed Hundreds Fear that the state betrayed the very patients it vowed to protect: over 100 plaintiffs were already dead while a senior judge begged the government to settle. How did pooled...
Fear that the state betrayed the very patients it vowed to protect: over 100 plaintiffs were already dead while a senior judge begged the government to settle. How did pooled plasma, US paid donors, and delayed heat‑treatment turn routine haemophilia care into a mass public‑health catastrophe - and when did officials know the risk?

In this episode, we tell the story of the HIV haemophilia litigation and the institutional decisions behind it, following the record that links product sourcing, regulatory choices, and internal memos to the rising toll. Can the documents recovered from the Department of Archives show what officials knew and why the government refused to act sooner?

Person: plaintiffs numbering 1,217
Date: litigation commenced April 1989
Location: England and Wales
Event: internal Department of Archives memorandum (drafted 1995) reported publicly 4 February 2022
Status: 107 plaintiffs dead by the time any settlement was reached; 23 more died before the case closed

- 1,217 people filed suit in the HIV haemophilia group action.
- 107 of those 1,217 were already dead by the time any settlement was reached.
- 163 plaintiffs had progressed to full AIDS by November 1989, seven months after the case began.
- 600 historic Department of Archives files (covering 1972-1986) were central to the case and withheld by the Department.
- The defendants included 220 institutions, among them the Department of Archives and regional health authorities.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1179falsefullhttps://www.spreaker.com/episode/when-cruisers-hit-medicine-the-missile-mistake-that-failed-tests--73098136
Fear that a single soil sample could justify destroying a nation's medicine supply: thirteen Tomahawk missiles hit a Khartoum pharmaceutical factory on August 20, 1998, after a private lab reported EMPTA at 2.5 times a trace threshold - yet no chemical weapons were ever found. How did a split sample, a classified operative, and ignored warnings lead to a strike that wiped out half of Sudan's drug production?

In this episode, we tell the recorded sequence of decisions and evidence that led to Operation Infinite Reach and its aftermath. We follow the timeline from the December 1997 soil sample and the CIA’s internal doubts to the factory's destruction and the unanswered questions about accountability.

Person: Salah Idris
Date: August 20, 1998
Location: Khartoum North
Event: Operation Infinite Reach strike on al-Shifa factory
Status: No chemical weapons found

- Thirteen Tomahawk cruise missiles struck the al-Shifa pharmaceutical factory on the evening of August 20, 1998.
- The factory produced more than half of Sudan’s pharmaceuticals, including malaria, tuberculosis, and insulin treatments.
- A soil sample collected in December 1997 showed EMPTA at roughly 2.5 times a trace threshold according to a private laboratory.
- The sample was split into three portions, lacked a verifiable chain of custody, and was analyzed by a single private lab without a second collection.
- One night watchman was killed and roughly 300 Sudanese workers lost their jobs when the factory was reduced to rubble.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098136Wed, 22 Jul 2026 02:50:43 +0000Creator at ObomediaWhen Cruisers Hit Medicine: The Missile Mistake That Failed Tests Fear that a single soil sample could justify destroying a nation's medicine supply: thirteen Tomahawk missiles hit a Khartoum pharmaceutical factory on August 20, 1998, after a...
Fear that a single soil sample could justify destroying a nation's medicine supply: thirteen Tomahawk missiles hit a Khartoum pharmaceutical factory on August 20, 1998, after a private lab reported EMPTA at 2.5 times a trace threshold - yet no chemical weapons were ever found. How did a split sample, a classified operative, and ignored warnings lead to a strike that wiped out half of Sudan's drug production?

In this episode, we tell the recorded sequence of decisions and evidence that led to Operation Infinite Reach and its aftermath. We follow the timeline from the December 1997 soil sample and the CIA’s internal doubts to the factory's destruction and the unanswered questions about accountability.

Person: Salah Idris
Date: August 20, 1998
Location: Khartoum North
Event: Operation Infinite Reach strike on al-Shifa factory
Status: No chemical weapons found

- Thirteen Tomahawk cruise missiles struck the al-Shifa pharmaceutical factory on the evening of August 20, 1998.
- The factory produced more than half of Sudan’s pharmaceuticals, including malaria, tuberculosis, and insulin treatments.
- A soil sample collected in December 1997 showed EMPTA at roughly 2.5 times a trace threshold according to a private laboratory.
- The sample was split into three portions, lacked a verifiable chain of custody, and was analyzed by a single private lab without a second collection.
- One night watchman was killed and roughly 300 Sudanese workers lost their jobs when the factory was reduced to rubble.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1307falsefullhttps://www.spreaker.com/episode/when-dissent-became-illness-the-soviet-science-of-silence--73098134
Fear that your conscience could be diagnosed as a disease: Soviet psychiatry turned dissent into "sluggish schizophrenia," a label that required no symptoms and erased people from public life. How did a diagnostic manual become a tool for indefinite detention and legal erasure?

In this episode, we trace the practice from a Moscow visit in February 1989 through earlier international precedents, following cases where political acts alone justified psychiatric confinement and asking how medicine was made to silence truth.

Person: Samuel Cartwright
Date: February 1989
Location: Moscow
Period: 19th-20th century
Case: "Sluggish schizophrenia"

- A team of American psychiatrists arrived in Moscow in February 1989 with a list of 48 names and managed to examine 27 people.
- Thirty-three names on that list correspond to patients whose ward locations no one would confirm and who exist only as names on a piece of paper.
- Samuel Cartwright published in 1851 diagnoses "drapetomania" and "dysaesthesia aethiopica" claiming conditions unique to enslaved Black people, with treatments including toe removal.
- Aurora D'Angelo attended a 1927 rally and was committed to a psychiatric institution shortly afterward; the record notes commitment based on political presence.
- Clennon King Jr. was taken from the University of Mississippi in 1958 and held secretly in a psychiatric facility for 12 days before doctors found him mentally healthy.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098134Wed, 22 Jul 2026 02:50:31 +0000Creator at ObomediaWhen Dissent Became Illness: The Soviet Science of Silence Fear that your conscience could be diagnosed as a disease: Soviet psychiatry turned dissent into "sluggish schizophrenia," a label that required no symptoms and erased people from public...
Fear that your conscience could be diagnosed as a disease: Soviet psychiatry turned dissent into "sluggish schizophrenia," a label that required no symptoms and erased people from public life. How did a diagnostic manual become a tool for indefinite detention and legal erasure?

In this episode, we trace the practice from a Moscow visit in February 1989 through earlier international precedents, following cases where political acts alone justified psychiatric confinement and asking how medicine was made to silence truth.

Person: Samuel Cartwright
Date: February 1989
Location: Moscow
Period: 19th-20th century
Case: "Sluggish schizophrenia"

- A team of American psychiatrists arrived in Moscow in February 1989 with a list of 48 names and managed to examine 27 people.
- Thirty-three names on that list correspond to patients whose ward locations no one would confirm and who exist only as names on a piece of paper.
- Samuel Cartwright published in 1851 diagnoses "drapetomania" and "dysaesthesia aethiopica" claiming conditions unique to enslaved Black people, with treatments including toe removal.
- Aurora D'Angelo attended a 1927 rally and was committed to a psychiatric institution shortly afterward; the record notes commitment based on political presence.
- Clennon King Jr. was taken from the University of Mississippi in 1958 and held secretly in a psychiatric facility for 12 days before doctors found him mentally healthy.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1263falsefullhttps://www.spreaker.com/episode/when-the-babysitter-is-the-weapon-the-hand-that-betrayed-home--73098131
Fear of the home being turned into a weapon: a graduate thesis script sold for $11.9 million and returned $140 million worldwide by turning domestic trust into menace-what happens when the person you invite in wants to destroy you? What made audiences recognize that dread so instantly?

In this episode, we tell the story of The Hand That Betrayed the Cradle from script to box office and explore how a film crafted to feel like it could happen on your block asked whether the spaces meant to protect us can be quietly turned against us. How did a thesis project become a cultural touchstone that rewired the idea of domestic safety?

Person: Amanda Silver
Director: Curtis Hanson
Opening weekend: January 10, 1992
Production budget: $11.9 million
Worldwide gross: $140 million

- The screenplay began as Amanda Silver's film school thesis and underwent roughly 30 drafts over two years.
- Interscope Communications acquired the project for Hollywood Pictures, with development reported in August 1990 and Curtis Hanson hired in October 1990.
- Principal photography began on April 15, 1991, after an original February start was delayed.
- The film opened January 10, 1992, earning $7.7 million its opening weekend and holding the top domestic box office spot for four weeks.
- Domestic gross was $88 million (United States and Canada) and international gross $52 million, a roughly 12:1 return on its $11.9 million budget.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098131Wed, 22 Jul 2026 02:50:19 +0000Creator at ObomediaWhen the Babysitter Is the Weapon: The Hand That Betrayed Home Fear of the home being turned into a weapon: a graduate thesis script sold for $11.9 million and returned $140 million worldwide by turning domestic trust into menace-what happens when...
Fear of the home being turned into a weapon: a graduate thesis script sold for $11.9 million and returned $140 million worldwide by turning domestic trust into menace-what happens when the person you invite in wants to destroy you? What made audiences recognize that dread so instantly?

In this episode, we tell the story of The Hand That Betrayed the Cradle from script to box office and explore how a film crafted to feel like it could happen on your block asked whether the spaces meant to protect us can be quietly turned against us. How did a thesis project become a cultural touchstone that rewired the idea of domestic safety?

Person: Amanda Silver
Director: Curtis Hanson
Opening weekend: January 10, 1992
Production budget: $11.9 million
Worldwide gross: $140 million

- The screenplay began as Amanda Silver's film school thesis and underwent roughly 30 drafts over two years.
- Interscope Communications acquired the project for Hollywood Pictures, with development reported in August 1990 and Curtis Hanson hired in October 1990.
- Principal photography began on April 15, 1991, after an original February start was delayed.
- The film opened January 10, 1992, earning $7.7 million its opening weekend and holding the top domestic box office spot for four weeks.
- Domestic gross was $88 million (United States and Canada) and international gross $52 million, a roughly 12:1 return on its $11.9 million budget.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1116falsefullhttps://www.spreaker.com/episode/restrained-for-ten-days-the-death-of-kelly-savage--73098127
Calm on admission yet bound at wrists, ankles and waist: a 27-year-old who spoke Japanese, held a university degree and loved the country where he taught was tied to a bed for days. Why did Yamato Hospital place a non-violent, described-as-calm patient in five-point restraints and keep him there through Golden Week?

In this episode, we tell the sequence of events from Kelly Savage’s life and hospitalization, tracing his move from Wellington to Japan, his JET teaching placement, a prior psychotic episode, and the final ten days in Yamato Hospital - and we ask how those contradictions in the medical record shaped the outcome.

Person: Kelly Robert Savage
Date of birth: 27 December 1989
Admission date: 30 April 2017
Location: Yamato Hospital, Kanagawa Prefecture, Japan
Family: Brother Patrick Savage; parents Michael and Martha Savage

- Kelly was admitted involuntarily to Yamato Hospital on 30 April 2017.
- Hospital admission records described Kelly as "calm" at the point of reception.
- Within hours of admission he was restrained at five points: wrists, ankles and waist.
- Kelly had a prior psychotic episode in 2012 and graduated from Victoria University in May 2015.
- He began taking psychiatric medication irregularly in early 2017 and stopped entirely before admission.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098127Wed, 22 Jul 2026 02:50:07 +0000Creator at ObomediaRestrained for Ten Days: The Death of Kelly Savage Calm on admission yet bound at wrists, ankles and waist: a 27-year-old who spoke Japanese, held a university degree and loved the country where he taught was tied to a bed for days. Why did Yamato...
Calm on admission yet bound at wrists, ankles and waist: a 27-year-old who spoke Japanese, held a university degree and loved the country where he taught was tied to a bed for days. Why did Yamato Hospital place a non-violent, described-as-calm patient in five-point restraints and keep him there through Golden Week?

In this episode, we tell the sequence of events from Kelly Savage’s life and hospitalization, tracing his move from Wellington to Japan, his JET teaching placement, a prior psychotic episode, and the final ten days in Yamato Hospital - and we ask how those contradictions in the medical record shaped the outcome.

Person: Kelly Robert Savage
Date of birth: 27 December 1989
Admission date: 30 April 2017
Location: Yamato Hospital, Kanagawa Prefecture, Japan
Family: Brother Patrick Savage; parents Michael and Martha Savage

- Kelly was admitted involuntarily to Yamato Hospital on 30 April 2017.
- Hospital admission records described Kelly as "calm" at the point of reception.
- Within hours of admission he was restrained at five points: wrists, ankles and waist.
- Kelly had a prior psychotic episode in 2012 and graduated from Victoria University in May 2015.
- He began taking psychiatric medication irregularly in early 2017 and stopped entirely before admission.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1191falsefullhttps://www.spreaker.com/episode/how-medical-science-built-itself-on-black-women-s-bodies-revealed--73098124
A chill of injustice runs through the history of medicine: tissue taken without consent, bodies exhibited in museums, and surgeries performed in daylight produced the very knowledge we now call progress. How did exhibitions in Paris and operating rooms in the American South set the stage for Henrietta Lacks’ cells to be taken, copied, and commodified without her knowledge?

In this episode, we trace the documented chain of three cases and three sets of women whose bodies and remains supplied material, publications, and medical practice; we follow the thread from 19th-century displays and dissections to a 1951 biopsy whose cells never died, and ask how institutions normalized taking Black bodies without consent.

Person: Henrietta Lacks
Date: January 1951 biopsy; October 1951 death
Location: Johns Hopkins Hospital, Baltimore
Event: First immortal human cell line named HeLa
Period: 1810-1815 (Sarah Baartman in Europe) through 1951 and up to 2023 settlement

- HeLa cells continued dividing in laboratories for at least seventy-two years after Henrietta Lacks’ 1951 biopsy.
- Henrietta Lacks was born in 1920, married at age 14, and had five children by age 30.
- Sarah Baartman arrived in Europe around 1810, was exhibited for five years, and died in Paris in 1815.
- Georges Cuvier dissected Baartman after death, preserved brain, genitalia, skeleton, and made a full body cast displayed at the Musée de l'Homme.
- In 2023 members of the Lacks family reached a legal settlement acknowledging Henrietta’s involuntary contribution.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>https://api.spreaker.com/episode/73098124Wed, 22 Jul 2026 02:49:54 +0000Creator at ObomediaHow Medical Science Built Itself on Black Women's Bodies Revealed A chill of injustice runs through the history of medicine: tissue taken without consent, bodies exhibited in museums, and surgeries performed in daylight produced the very knowledge...
A chill of injustice runs through the history of medicine: tissue taken without consent, bodies exhibited in museums, and surgeries performed in daylight produced the very knowledge we now call progress. How did exhibitions in Paris and operating rooms in the American South set the stage for Henrietta Lacks’ cells to be taken, copied, and commodified without her knowledge?

In this episode, we trace the documented chain of three cases and three sets of women whose bodies and remains supplied material, publications, and medical practice; we follow the thread from 19th-century displays and dissections to a 1951 biopsy whose cells never died, and ask how institutions normalized taking Black bodies without consent.

Person: Henrietta Lacks
Date: January 1951 biopsy; October 1951 death
Location: Johns Hopkins Hospital, Baltimore
Event: First immortal human cell line named HeLa
Period: 1810-1815 (Sarah Baartman in Europe) through 1951 and up to 2023 settlement

- HeLa cells continued dividing in laboratories for at least seventy-two years after Henrietta Lacks’ 1951 biopsy.
- Henrietta Lacks was born in 1920, married at age 14, and had five children by age 30.
- Sarah Baartman arrived in Europe around 1810, was exhibited for five years, and died in Paris in 1815.
- Georges Cuvier dissected Baartman after death, preserved brain, genitalia, skeleton, and made a full body cast displayed at the Musée de l'Homme.
- In 2023 members of the Lacks family reached a legal settlement acknowledging Henrietta’s involuntary contribution.

To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.]]>1022falsefull